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SUMMARY 
 
The increasing resistance of pathogenic bacteria to existing antibiotics has become one of 
the most serious threats to public health, and the discovery and development of new 
antibiotics represents an enormous challenge both for industry and for academic research 
institutions. 
 
Aminocoumarin antibiotics like clorobiocin, novobiocin and coumermycin A1 are produced 
by different Streptomyces strains. Their biosynthetic gene clusters have been cloned and 
sequenced, and the function of nearly all genes therein has been elucidated. With this 
knowledge, new derivatives of these antibiotics were generated by genetic engineering, 
mutasynthesis and combinatorial biosynthesis over the past years. In contrast to 
fluoroquinolones, aminocoumarins are potent inhibitors of the GyrB subunit of the bacterial 
DNA gyrase by competing with the binding of ATP. They are active against Gram-positive 
pathogens including methicillin-resistant Staphylococcus aureus strains and have also 
potential applications in oncology. It has been shown that they enhance the cytotoxic 
activities of the anti-tumor drugs etoposide and teniposide and interact with the eucaryotic 
heat shock protein 90 (Hsp90). Only novobiocin had been licensed for clinical use in 
human infections in the United States (Albamycin®). Because of the low solubility in water, 
toxicity in eukaryotes and poor penetration in Gram-negative bacteria the therapeutic use 
of aminocoumarin antibiotics remain restricted. Combinatorial biosynthesis may offer a 
way to develop novel aminocoumarins with improved properties.  
 
Previous date indicated that the lack of antibiotic activity of aminocoumarins against Gram-
negative bacteria was in part due to their poor permeation across the outer membrane. In 
this work, we aimed to generate a siderophore-like derivative of clorobiocin, which mimicks 
the structure of siderophores. This would facilitate the active transport of the antibiotic into 
the cell by its own siderophore transporters. In the first part of this PhD work, the 
prenylated 4-hydroxybenzoyl moiety (Ring A) of clorobiocin was replaced with a 3,4-
dihydroxybenzoyl moiety using combinatorial biosynthesis techniques. An artificial operon 
was synthesized, consisting of the genes for chorismate pyruvate lyase of E. coli and for 4-
hydroxybenzoate 3-hydroxylase of Corynebacterium cyclohexanicum. This operon, 
directing the biosynthesis of 3,4-dihdroxybenzoate, was expressed in the heterologous 
host Streptomyces coelicolor M512, together with a modified clorobiocin gene cluster that 
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lacks an essential gene for the biosynthesis of the genuine Ring A. The resulting strain 
now produced a new clorobiocin derivative containing a 3,4-dihdroxybenzoyl moiety. Its 
structure was confirmed by LC-MS, HR-MS and NMR analysis, and it was found to be a 
potent inhibitor of the DNA gyrase from E. coli and Staphylococcus aureus. These 
experiments confirmed that the structure of Ring A is not essential for the interaction with 
DNA gyrase. Bioassays against different E. coli mutants suggested that this compound 
(novclobiocin 401) was actively imported by catechol siderophore transporters in the cell 
envelope. This study provides a new example that the structure of a natural product can 
be rationally modified by genetic methods. 
Experiments to generate other siderophore-like derivatives of clorobiocin were performed. 
Substitution of Ring A with 2,3-dihydroxybenzoic acid (2,3-DHBA), which is the catechol 
moiety present in the siderophore enterobactin of Escherichia coli, was achieved at the 
end of this PhD work. The limiting biosynthetic steps were identified by in vitro assays: 2,3-
DHBA must be first activated by adenylation –attained with the AMP ligase DhbE from 
Bacillus subtilis– before being accepted by the available aminocoumarin acyl ligases as 
substrate. 
 
In the second project, we investigated the inhibitory activity of the naturally occurring 
aminocoumarin antibiotics novobiocin, clorobiocin, coumermycin A1, simocyclinone D8 and 
of several new derivatives (novclobiocins) against DNA gyrase and topoisomerase IV from 
Escherichia coli and Staphylococcus aureus as well as the effect of potassium and sodium 
glutamate on the activity of these enzymes. For this purpose, the inhibitory concentrations 
of the aminocoumarins were determined in DNA gyrase supercoiling assays and 
topoisomerase IV decatenation assays. Both subunits of S. aureus topoisomerase IV were 
purified by expressing the genes encoding the subunits ParC and ParE separately as His-
Tag proteins in Escherichia coli. DNA gyrase is in vitro the primary target of all investigated 
aminocoumarins. With the exception of simocyclinone D8, all other aminocoumarins 
inhibited S. aureus DNA gyrase on average 6-fold more effectively than E. coli DNA 
gyrase. Potassium glutamate was found to be essential for the activity of S. aureus DNA 
gyrase and increased the sensitivity of E. coli DNA gyrase to aminocoumarins at least 10-
fold. Furthermore, the IC50 values were three orders of magnitude lower than those 
reported for fluoroquinolones. This study provides insights about the important substituents 
for the inhibitory activity of aminocoumarins against the target enzymes, and thereby may 
facilitate the rational design of improved antibiotics. 
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ZUSAMMENFASSUNG 
 
Die steigende Resistenz pathogener Bakterien gegenüber bekannten Antibiotika wird 
immer mehr zu einer ernstzunehmende Bedrohung der Gesundheit und die Entdeckung 
und Erforschung neuer wirksamer Antibiotika zu einer schwierigen Herausforderung. 
Aminocoumarine, wie z.B. Novobiocin, Clorobiocin oder Coumermycin A1, bilden eine 
interessante Gruppe von Antibiotika, die von verschiedenen Stämmen der Gattung 
Streptomyces gebildet werden. Ihre Biosynthesegencluster wurden in den vergangenen 
Jahren kloniert, sequenziert und die Funktion nahezu aller Gene aufgeklärt. Mit diesem 
Wissen konnten neue Derivate dieser Antibiotika durch genetische Manipulation, 
Mutasynthese und Kombinatorische Biosynthese hergestellt werden.  
Im Gegensatz zu Chinolon-Antibiotika, die an der A-Untereinheit der bakteriellen Gyrase 
angreifen, ist das zelluläre Traget der Aminocoumarine die B-Untereinheit. Das 
therapeutische Potential der Aminocoumarine liegt in ihrer hohen Affinität zur bakteriellen 
Gyrase mit Inhibierungskonzentrationen im 10 nM Bereich; d.h. die Hemmkonzentrationen 
sind erheblich geringer als die der Chinolone.  
Neben ihrer Wirkung als Antiinfektiva gegen Gram-positive Pathogene (methicillin-
resistente Staphylococcus aureus Stämme eingeschlossen) finden sie außerdem 
Anwendung in der Onkologie. Aminocoumarine potenzieren zum einen die zytotoxische 
Wirkung der Topoisomerase-Inhibitoren Etoposid und Teniposid und reduzieren zum 
anderen durch direkte Interaktion mit dem Heat shock Protein 90 (Hsp90) die Menge an 
onkogenen Protein Kinasen (z.B. Raf-1) und somit die Anzahl an Tumorzellen.  
Obwohl Clorobiocin der potentere Wirkstoff gegen die bakterielle Gyrase ist, ist einzig 
Novobiocin in den USA als humantherapeutisches Antiinfektivum unter dem 
Handelsnamen Albamycin® (Pharmacia & Upjohn) zugelassen und wird zur Behandlung 
multiresistenter Gram-positiver Pathogene wie Staphylococcus aureus und 
Staphylococcus epidermidis eingesetzt. Wegen der schlechten Löslichkeit in Wasser, der 
Toxizität gegenüber eukaryotischen Zellen und der geringen Aktivität gegen Gram-
negative Bakterien, wird Novobiocin allerdings nur als Reserveantibiotikum verwendet. 
Kombinatorische Biosynthese bietet daher eine viel versprechende Möglichkeit neue 
Aminocoumarin-Antibiotika mit verbesserten Eigenschaften zu entwickeln. 
 
Zu Beginn dieser Doktorarbeit wurde angenommen, dass die schlechte Wirkung von 
Aminocoumarinen auf die unzulängliche Penetration durch die äußere Membran Gram-
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negativer Bakterien zurückzuführen ist. Wir stellten daraufhin mittels Kombinatorischer 
Biosynthese ein Clorobiocin Derivat mit einer siderophor-ähnlichen Struktureinheit her, mit 
deren Hilfe der aktive Transport durch die äußere Membran mittels zelleigenen 
Siderophortransporter genutzt werden sollte. Hierfür wurde die prenylierte 4-
Hydroxybenzoesäure (Ring A) von Clorobiocin durch 3,4-Dihydroxybenzoesäure (3,4-
DHBS) ersetzt. Zuvor wurde ein Operon aus zwei synthetischen Genen erstellt, die für 
eine Pyruvatlyase und eine 4-Hydroxybenzoat-3-hydroxylase kodieren und zusammen für 
die Biosynthese der 3,4-DHBS verantwortlich sind. Die Gene stammen aus dem Gram-
negativen Bakterium E. coli und dem Gram-positiven Bakterium Corynebacterium 
cyclohexanicum. Die Codons beider Gensequenzen wurden für eine Expression im 
Wirtsstamm Streptomyces coelicolor M512 optimiert und zusammen mit einem cloQ-
defekten Clorobiocin Biosynthesegencluster (verantwortlich für das Ausbleiben der Ring A-
Biosynthese) transformiert. Der resultierende Stamm produzierte ein neues Clorobiocin 
Derivat (Novclobiocin 401) mit der siderophor-ähnlichen Struktureinheit 3,4-DHBS. Die 
chemische Struktur des neuen Clorobiocin Derivats wurde mittels LC-MS, HR-MS und 
NMR Analysen bestätigt.  
Novclobiocin 401 erwies sich als potenter Hemmstoff der bakteriellen Gyrase von 
Escherichia coli und Staphylococcus aureus, was die Vermutung bestätigte, dass Ring A 
nicht an der direkten Interaktion mit der bakteriellen Gyrase beteiligt ist. Bioassays gegen 
verschiedene Escherichia coli Mutanten zeigten, dass diese Substanz aktiv durch 
Catecholsiderophortransporter in die Zelle transportiert wurde. Anhand dieser Arbeit 
konnte gezeigt werden, dass neue potente Substanzen bewusst durch „synthetische 
Biologie“ hergestellt werden können.  
 
Im Laufe dieser Arbeit wurde außerdem erstrebt, andere siderophor-ähnliche Clorobiocin 
Derivate herzustellen. Eine Substitution von Ring A mit 2,3-Dihydroxybenzoesäure (2,3-
DHBS), der Catecholeinheit der Siderophore Enterobactin von Escherichia coli, wurde 
schlussendlich erhalten, nachdem der limitierende Schritt durch in vitro Assays identifiziert 
wurde: 2,3-DHBS musste erst durch Adenylierung aktiviert werden, was durch Inkubation 
mit der AMP Ligase DhbE aus Bacillus subtilis erreicht wurde. Erst die aktivierte 2,3-DHBS 
wurde danach von allen uns vorliegenden Aminocoumarin-Acyl Ligase als Substrat 
akzeptiert. 
 
Im zweiten Projekt wurde die inhibitorische Aktivität der natürlichen Aminocoumarine 
Clorobiocin, Novobiocin, Coumermycin A1, Simocyclinon D8 und mehrere Aminocoumarin 
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Derivate (Novclobiocine) gegen die bakterielle Gyrase und Topoisomerase IV von 
Escherichia coli und Staphylococcus aureus untersucht. Außerdem wurde der Effekt von 
Kaliumglutamat (K-Glu) auf die Aktivität der Topoisomerasen bestimmt. Die 
Inhibierungskonzentartionen der Aminocoumarine wurden in Gyrase-Supercoiling Assays 
bzw. Topoisomerase IV-Dekatenierungs Assays bestimmt. Beide Untereinheiten der S. 
aureus Topoisomerase IV, ParC und ParE, wurden exprimiert und mittels Nickel-
Affinitätschromatographie gereinigt. Die bakterielle Gyrase erwies sich in den in vitro 
Assays als bevorzugte Zielstruktur aller getesteten Aminocoumarine. Mit Ausnahme von 
Simocyclinon D8 wurde die S. aureus gyrase im Durchschnitt sechsmal besser als die E. 
coli Gyrase gehemmt. Kaliumglutamat erwies sich als unabkömmlich für die Aktivität der 
S. aureus Gyrase und steigerte die Sensitivität der E. coli Gyrase mindestens um das 10-
fache. Die Ergebnisse dieses Projektes zeigten die Wichtigkeit verschiedener 
Substituenten der Aminocoumarin Derivate für die Interaktion mit ihren Zielstrukturen, was 
für das Design zukünftiger potenter Aminocoumarine von Wichtigkeit sein kann.  
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I. INTRODUCTION 
I.1. Antibiotic resistance and the quest for new antibiotics  
 
The dramatic increase in the number of antibiotic-resistant pathogenic Gram-positive and 
Gram-negative bacteria in the past decade have focused attention on the need for new 
anti-infective drugs119. Natural products have traditionally played a dominant role in the 
discovery of new drugs, although structural modifications of these natural products are 
often necessary to improve the efficacy, stability and pharmacokinetics124. 
 
About two-thirds of the known antibiotics, and many other compounds with different 
biological activities, are produced by a group of Gram-positive bacteria called 
actinomycetes9, characterised by the high content of guanine and cytosine of their 
genomes125 (in contrast with the other main group of Gram-positive bacteria, the low G+C 
organisms, which includes genera such as Bacillus or Staphylococcus). Among 
actinomycetes, the most prolific producers of antibiotics are the species of the genus 
Streptomyces. Streptomyces are ubiquitous soil bacteria, where they play a central role in 
carbon recycling. They show one of the most complex life cycles among bacteria: a spore 
germinates leading to the development of a vegetative mycelium that differentiates in 
aerial hyphae and later in chains of spores, facilitating the dispersion of the specie as well 
as its survival under adverse conditions. The production of antibiotics is usually 
coordinated with the morphological differentiation59. 
 
The history of antibiotics obtained from Streptomyces begins with the discovery of 
streptothricin in 1942, although it was the discovery of streptomycin two years later what 
triggered systematic screening of antibiotics produced by members of this genus122. 
Streptomyces coelicolor A3(2) is the most studied representative of this genus. This strain 
is able to produce four known chromosomally encoded antibiotics: the NRPS/PKS-derived 
prodiginines, the type II polyketide actinorhodin, the NRPS-derived calcium-dependent 
antibiotic (CDA) and the type I polyketide CPK11.  
 
Antibiotic production in Streptomyces is generally growth phase-dependent. In liquid 
culture it begins as the culture enters stationary phase. Most antibiotics are the products of 
complex biosynthetic pathways, with all the enzymes and transport proteins encoded 
within a gene cluster that usually contains also genes for pathway-specific transcriptional 
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regulatory proteins. The onset of antibiotic biosynthesis is determined and influenced by a 
variety of physiological and environmental factors. There is evidence that the full capacity 
for secondary metabolite production by soil microorganisms is not expressed under the 
typical conditions used for antibiotic screening in the laboratory. Furthermore, only a small 
portion of microorganisms are culturable by current methods. Therefore, it is accepted that 
a large number of biosynthetic pathways still await to be discovered in actinomycetes, 
what encourages the use of genetic approaches for antibiotic discovery, like heterologous 
expression of biosynthetic gene clusters in culturable and genetic manipulable strains (e.g. 
Streptomyces coelicolor M51238 and combinatorial biosynthesis or genetic engineering as 
methods to increase the natural diversity120. 
 
In 1985, Hopwood55 reported 1985 for the first time the production of “hybrid” antibiotics by 
genetic engineering of Streptomyces strains, i.e. through the transfer of biosynthetic genes 
between strains producing different members of the same class of antibiotics in order to 
combine structural features of both compounds. Since then, the number of biosynthetic 
genes and gene clusters available for such experiments, and the genetic techniques 
available for recombination and expression, have expanded greatly and many new 
bioactive compounds have been generated by genetic engineering of microorganisms53, 54. 
Advances in the methods of chemical DNA synthesis now allow to readily adapt the 
sequence of a gene to different expression hosts, what greatly expands the possibilities for 
the generation of new bioactive compounds by the combination of genes from very 
different organisms. This "combinatorial biosynthesis", or the shuffling of biosynthetic 
genes from different pathways and even organisms via genetic engineering to create novel 
chemical structures, has proved in the last few years to represent a promising alternative 
approach to create new compounds and overcome bacterial resistance to existing drugs21, 
76, 119.  
 
Over the last years, the biosynthetic gene clusters of five different aminocoumarin 
antibiotics have been cloned and sequenced, and this group of antibiotics has become a 
successful example for the generation of new derivatives in high structural diversity by 
combinatorial biosynthesis techniques, including metabolic engineering, mutasynthesis, 
and chemoenzymatic synthesis in natural and heterologous producer strains65, 35, 48. 
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I.2. Aminocoumarin antibiotics 
I.2.1. Chemical structure 
 
The aminocoumarin antibiotics are produced by different Streptomyces strains: e.g. 
novobiocin by S. spheroides111, clorobiocin by S. roseochromogenes var. oscitans DC 
12.97672, and coumermycin A1 by S. rishiriensis13. So far, two further aminocoumarin 
antibiotics, simocyclinone D8101 and rubradirin109 have been discovered (Figure I.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.1: 
Chemical structure of the aminocoumarin antibiotics. 
 
The characteristic structural moiety that gives the name to the aminocoumarin antibiotics is 
a 3-amino-4,7-dihydroxycoumarin moiety (Ring B), which is linked via an amide bond to an 
acyl moiety (Ring A) and via a glycosidic bond to the deoxysugar noviose (Ring C)49. 
Clorobiocin differs from novobiocin at two positions: novobiocin has a carbamoyl group 
attached to noviose, while clorobiocin contains a 5-methylpyrrole-2-carboxylic acid 
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molecule, and clorobiocin carries a chlorine atom at Ring B whereas novobiocin has a 
methyl group at the corresponding position (Figure I.1). Coumermycin A1 contains two 
noviosyl aminocoumarin moieties and has a different acyl component, 3-methyl-pyrrole-
2,4-dicarboxylic acid. Simocyclinone D8 and rubradirin have only Ring B in common with 
the “classical” aminocoumarins49. 
 
 
I.2.2. Mechanism of action 
 
The mode of action of clorobiocin, novobiocin and simococlinone D8 has been examined 
recently by Maxwell and Lawson74. These aminocoumarins are powerful inhibitors of DNA 
gyrase, binding to this target with higher affinity than modern fluoroquinolones.  
Gyrase and topoisomerase IV belong to the procaryotic type II topoisomerases22, 104, that 
are different from eukaryotic topoisomerases and therefore they are a promising anti-
infective drug target. Topoisomerases can be divided into two main classes: type I 
enzymes, which cleave a single strand of DNA during the course of their reaction, and type 
II enzymes, which cleave both strands. DNA gyrase is unique in its ability to introduce 
negative supercoils into DNA and is involved in the maintenance of a critical superhelical 
density of DNA that is essential for DNA replication and transcription. In contrast, the 
primary function of topoisomerase IV is the decatenation of multiply linked daughter 
chromosomes during the terminal stages of DNA replication (Figure I.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.2107: 
Reactions of type II topoisomerases. 
(A) DNA gyrase introduces negative 
supercoils into closed circular DNA by 
the concerted breaking and rejoining of 
double strands. Both DNA gyrase and 
topoisomerase IV can remove supercoils. 
(B) Supercoiled DNA is catenated by 
DNA gyrase and decatenated by both 
DNA gyrase and topoisomerase IV. 
DNA gyrase
DNA gyrase and topoisomerase IV
catenane
decatenation
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INTRODUCTION 
 
14 
DNA gyrase as well as topoisomerase IV consist of two GyrA/GyrB and two ParC/ParE 
subunits, respectively. The reactions catalysed by both enzymes are energetically driven 
by hydrolysis of ATP, catalysed by GyrB and ParE subunits22, 104.  
Aminocoumarins bind to the GyrB subunit of DNA gyrase or the ParE subunit of 
topoisomerase IV, competing with the binding of ATP10, 74. Detailed crystallographic 
studies have been published on the interaction of clorobiocin and novobiocin with DNA 
gyrase and topoisomerase IV, which have shown that Ring B and Ring C are essential for 
the interactions with gyrase, while Ring A is much less involved in the binding of the 
antibiotics to the target. Therefore, it appears possible to vary the structure of Ring A 
without severely affecting the DNA gyrase inhibitory activity. Complexes between 
clorobiocin or novobiocin and the protein involve hydrophobic interactions and a network of 
hydrogen bonds. Key hydrogen bonds include those between Arg136 and Ring B, Asp73 
and Thr65 and the acyl group of Ring C, and Asn46 and the hydroxyl group of Ring C 
(Figure I.3)74. The drugs do not occupy the same binding pocket as ATP, but the binding 
site of Ring C overlaps with the binding site for the adenine ring of ATP86. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.3: 
(A) Interaction between E. coli gyrase subunit B and clorobiocin; adapted from ref. 74; (B) Interaction 
between E. coli gyrase subunit B and ATP; adapted from ref. 86.   
 
The interest in aminocoumarins has been stimulated by recent biochemical and X-ray 
crystallographic evidence showing that the aminocoumarin antibiotic simocyclinone D8 
inhibits DNA gyrase by a completely new mode of action, interacting with two separate 
pockets of the enzyme and thereby preventing its binding to DNA30, 36, 87.  
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I.2.3. Clinical application 
 
The therapeutic potential of the aminocoumarins lies especially in their very high affinity to 
gyrase. Their equilibrium dissociation constants (KD) for gyrase is in the 10 nM range, i.e. 
lower than that of fluoroquinolones74. 
Even though clorobiocin is a more potent inhibitor of DNA gyrase, only novobiocin 
(Albamycin®, Pharmacia & Upjohn) has been licensed in the United States for the 
treatment of human infections with multi resistant bacteria such as Staphylococcus aureus 
and Staphylococcus epidermidis6. Due to its poor solubility in water, which prevented the 
development of parenteral formulations, the toxicity in eukaryotes and its low activity 
against Gram-negative bacteria (resulting from poor permability), clinical use of this 
antibiotic remains restricted. 
Novobiocin and its derivatives have also been investigated as potential anticancer drugs. 
Novobiocin acts synergistically with etoposide and teniposide and could be used in 
combination therapies to overcome drug resistance. The increase in etoposide cytotoxicity 
is due to the inhibition by novobiocin of etoposide efflux68, 95-97. Furthermore, novobiocin, 
clorobiocin, and coumermycin A1 were shown to interact with the eukaryotic heat shock 
protein 90 (Hsp90), which plays a key role in the stability and function of multiple cell-
signaling components, e.g. several oncogenic tyrosine and serine-threonine kinases (e.g. 
Raf-1), being expressed at two to ten fold higher levels in tumour cells than in their normal 
counterparts. Hsp90 is therefore considered to be a novel molecular target for anticancer 
therapeutics, and aminocoumarins markedly reduced cellular levels of oncogenic kinases 
in vitro and in vivo (mice) by interacting with Hsp9073. 
 
 
I.2.4. Biosynthesis and biosynthetic gene clusters  
 
The biosynthesis of novobiocin was first studied in the 1960s by feeding experiments by 
Birch and co-workers14 and Bunton and co-workers20. They proved that the deoxysugar is 
derived from glucose, and that tyrosine is the precursor of both the aminocoumarin moiety 
(Ring B) and the acyl component (Ring A). In 2000, cloning and sequencing of the 
novobiocin biosynthetic gene cluster provided the basis for genetic investigations of 
aminocoumarin antibiotics biosynthesis111. Subsequently, the biosynthetic gene clusters 
for coumermycin A1 and clorobiocin were also identified92, 121. Comparison of the three 
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gene clusters revealed a strikingly stringent correspondence between the structure of the 
antibiotics and the organization of the biosynthetic genes (Figure I.4). The order of the 
genes coding for each structural moiety are perfectly identical for the three clusters. The 
novobiocin, clorobiocin and coumermycin A1 cluster span 23.4, 35.6 and 38.2 kb and 
comprise 20, 29 and 31 putative genes, respectively66. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.4: 
The biosynthetic gene clusters of coumermycin A1 (cou), clorobiocin (clo) and novobiocin (nov).  
  
The 3-amino-4,7-dihydroxy coumarin moiety (Ring B) is present in all three 
aminocoumarins, and correspondingly all three clusters contain a group of four genes for 
its biosynthesis, i.e. novHIJK, cloHIJK and couHIJK23. 
The 3-prenylated-4-hydroxybenzoyl moiety (Ring A) of clorobiocin (and of novobiocin) is 
formed from 4-hydroxyphenylpyruvate under catalysis of the ABBA prenyltransferases 
CloQ93 (NovQ) and two subsequent oxidative decarboxylation steps catalysed by the non-
heme iron(II)-and α-ketoacid-dependent oxygenase CloR91 (NovR). The prephenate 
dehydrogenases CloF (NovF) provides 4-hydroxyphenylpyruvate34.  
The aminocoumarin moiety is linked to the respective acyl moiety by the amide synthetase 
NovL110, CloL43 or CouL103. 
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The aminocoumarin moieties of novobiocin and coumermycin A1 are methylated by the 
methyl transferases NovO and CouO respectively67. Clorobiocin contains a chlorine atom 
and correspondingly the gene cluster of clorobiocin contains a gene clo-hal encoding a 
halogenase32. 
All three aminocoumarin antibiotics contain the same deoxysugar skeleton92, 111, 121, i.e. 5-
C-methyl-L-rhamnose, and all three gene clusters contain a group of five genes, 
novSTUVW and its orthologous in the other clusters. The dTDP-activated deoxysugar is 
subsequently transferred to the 7-hydroxy group of the aminocoumarin moiety, catalysed 
by the glycosyl transferases NovM39, CloM and CouM. 
After glycoside formation, the 4-hydroxy group of the deoxysugar is methylated by the 
SAM-dependent methyltransferases NovP40, CloP or CouP. 
The last step in the biosynthesis appears to be the acylation of the 3-hydroxy group of the 
deoxysugar, catalysed in novobiocin biosynthesis by the carbamoyl transferase NovN40. In 
clorobiocin and coumermycin A1, the corresponding acyl moiety is a pyrrol-2-carboxylic 
acid formed by the genes cloN1-73 and couN1-7 (Figure I.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.5: 
Structure of clorobiocin and function of the gene products of cloFHIJKLMNPQRSTUVW and clo-hal in 
clorobiocin biosynthesis49. 
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The clorobiocin and coumermycin A1 gene clusters contain a small open reading frame, 
cloY and couY, which shows sequence similarity to the gene mbtH from the biosynthetic 
gene cluster of the siderophore mycobactin from Mycobacterium tuberculosis. It is 
supposed that these genes interact with cloH (couH) in an adenylation reaction of L-
tyrosine128. 
All three clusters contain also two positive regulators, novE34 and novG33 and their 
orthologs, as well as a gyrBR resistance gene, coding an aminocoumarin-resistant gyrase 
B subunit. The gene clusters of clorobiocin and coumermycin A1 contain an additional 
resistance gene parYR102. This encodes an aminocoumarin resistant topoisomerase IV 
subunit. Clorobiocin and coumermycin A1 are more potent inhibitors of topoisomerase IV 
than novobiocin, and therefore it makes sense that during the evolution of the biosynthetic 
gene clusters the clorobiocin and coumermycin A1 producers had to acquire a second 
resistance gene. 
 
 
I.2.5. Bacterial resistance mechanisms against aminocoumarins 
 
A principal shortcoming of the aminocoumarin antibiotics is their poor activity against 
Gram-negative organisms which is due to a synergistic effect of the permeability barrier, 
imposed by the outer membrane114, and of active efflux by multidrug efflux pumps of these 
organisms81. The outer membrane bilayer is composed of lipopolysaccarides85. Because 
of the presence of porins12, protein complexes that cross the membrane forming a pore 
through which small molecules can diffuse with different selectivity, the outer membrane is 
permeable for small hydrophilic substances but not for hydrophobic compounds or 
molecules with higher molecular weight.  
The multidrug efflux pump is another worrisome mechanism that contributes to bacterial 
antibiotic resistance. Active efflux is a mechanism responsible for the export of a variety of 
antibiotics outside the bacterial cell. The ability of efflux systems to recognize a large 
number of compounds other than their natural substrates is probably because substrate 
recognition is based on physiochemical properties, such as hydrophobicity, aromaticity 
and ionisable character, rather than on defined chemical properties as, for instance, in 
classical enzyme-substrate or ligand-receptor recognition. Because aminocoumarins are 
amphiphilic molecules they are easily recognized by many efflux pumps84, e.g. the 
multidrug transporter ABC (mdtABC or AcrAB)81, 7. This efflux system usually consists of 
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membrane protein complexes, e.g. MdtA/MdtB/MdtC or AcrA/AcrB, and a common 
membrane channel TolC (Figure I.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.6: 
Schematic model of the molecular construction of MdtABC-TolC and AcrAB-TolC transporter complexes, 
respectively; adapted from ref. 81. 
 
Since efflux pump inhibitors, like verapamil, can be used in combination with current drugs 
to increase their effective intracellular concentration, the possible impact of efflux pump 
inhibitors together with improved uptake of the antibiotic is of great clinical interest94. 
 
 
I.2.6. Transport of catechol siderophores 
 
In the outer membrane bilayer reside various specific transporters for the uptake of 
essential nutrients. Iron is an essential trace nutrient for most known organisms for 
processes such as respiration and DNA synthesis. Despite being one of the most 
abundant elements in the earth crust, the bioavailability of iron in many oxygenated 
environments such as the soil or sea is limited by very low solubility of the Fe3+ ion, form 
not readily usable by organisms. 
Gram-negative bacteria produce and secrete iron-chelating molecules that efficiently bind 
iron (siderophores) and possess specific receptors in the outer membrane (e.g. E. coli Cir, 
Fiu and FepA) that facilitate the active transport of the siderophore-iron complex into the 
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cell82. Many siderophores, like E. coli enterobactin, contain catechol (= o-diphenol) motifs 
whose proximate hydroxyl groups are responsible for chelating the Fe3+ ion. In the case of 
E. coli Cir, Fiu and FepA transporters, they receive the energy for active transport from the 
inner membrane associated proteins TonB, ExbB and ExbD. After passing the outer 
membrane, the siderophore-iron(III) complex is bound by a periplasmic binding protein 
(PBP). The PBP donates the ferrisiderophore to a transporter and once inside the 
cytoplasm a reductase releases iron under the Fe2+ form, which can be incorporated into 
Fe-containing proteins. The siderophore can eventually be recycled (Figure I.7)25. The 
expression of this machinery is up-regulated under conditions of iron starvation. Bacterial 
growth during an infection in the human body represents a condition of extreme iron 
starvation24, and therefore the bacterial iron uptake mechanism offers a possibility to 
overcome membrane-associated drug resistance by a Trojan Horse approach.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.7: 
Schematic representation of the uptake of iron via siderophores in Gram-negative bacteria. OM = outer 
membrane; IM = inner membrane; adapted from 25.  
 
It has been shown that beta-lactam antibiotics to which a catechol moiety had been 
chemically attached were transported by siderophore transporters into the Gram-negative 
cell, resulting in an enhanced antibacterial activity79. As it was discussed earlier, 
aminocoumarin antibiotics have potent antibacterial activity against Gram-positive bacteria 
but little against Gram-negative microorganisms, partly due to the lack of permeability. 
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Therefore, it was of great interest to develop aminocoumarin derivatives with siderophore-
like structures, so that the aminocoumarin antibiotic is recognized and actively transported 
into the cell under involvement of catechol siderophore transporters (Figure I.8) and in this 
way to obtain new antibiotics that could add to the scarce set of available compounds to 
fight the increasing problem of multi-drug resistant Gram-negative infections61. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.8: 
Aminocoumarin derivative imitating the siderophore-like structure (catechol) of a siderophore, e.g. 
enterobactin from Escherichia coli. 
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I.3. Objectives of this study 
 
 
The principal objectives of this study were: 
 
 
1) To generate new aminocoumarin derivatives with catechol structures instead of 
the natural Ring A by metabolic engineering, mutasynthesis and combinatorial 
biosynthesis for studies of influx and efflux processes. 
The bacterial cell envelope represents a barrier, which strongly limits the efficacy of 
many antibiotics. We attempted to develop new catechol derivatives in order to test 
whether they would be transported into the cell under involvement of catechol 
siderophore transporters. 
 
 
2) To generate mutants of E. coli with multiple mutations affecting transport 
processes in the bacterial cell envelope. 
E. coli mutants with a single gene exchanged by an antibiotic resistance cassette are 
available from the Keio-strain collection (Japan). Further deletions of genes of interest 
by RED/ET-mediated recombination were necessary to study siderophore dependent 
uptake processes of the newly generated catechol compounds. Also, the export of 
aminocoumarins by multidrug efflux pumps shall be examined via these E. coli mutant 
strains. 
 
 
3) To investigate the antibacterial activity of these new catechol derivatives against 
different E. coli mutant strains in agar diffusion tests (bioassays). 
To investigate whether catechol-containing aminocoumarins are subject to active 
import by catechol siderophore transporters, the expression of these transporters 
needs to be induced by iron-limited growth conditions. Under these conditions, 
siderophore-dependent uptake of the compounds shall be identified and the minimum 
inhibitory concentration of compound necessary to avoid bacterial growth determined. 
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4) To express and purify both subunits ParC and ParE of Staphylococcus aureus 
topoismoerase IV for the investigation of aminocoumarins activity against this 
target. 
S. aureus DNA gyrase, as well as E. coli topoisomerase IV and DNA gyrase, were 
available commercially, but it was necessary to purify S. aureus topoisomerase IV for 
our study. Soluble, N-terminally his-tagged proteins were aimed to be obtained by 
expression in Escherichia coli host cells of constructs containing parC and parE from 
the methicillin-resistant strain S. aureus RN4220. 
 
 
5) To determine the inhibitory activity of the new catechol derivatives as well as 
other derivatives of clorobiocin and novobiocin, called novclobiocins, against 
their principal targets, gyrase and topoisomerase IV of Escherichia coli and 
Staphylococcus aureus.  
Structural changes of aminocoumarins may not only affect their recognition by active 
transport systems in the bacterial cell envelope, but also their affinity to their biological 
targets, gyrase and topoisomerase IV. Therefore, the compounds generated in this 
project, as well as other novclobiocins produced in our lab, should be tested against 
these two targets in supercoiling and decatenation assays, and their activities be 
compared with those of the natural aminocoumarins clorobiocin, novobiocin, 
coumermycin A1 and simocyclinone D8. 
 
 
6) To provide a new clorobiocin cloHIJK (Ring B synthesis) defective mutant strain, 
unable to produce the natural Ring B, for the generation of new aminocoumarin 
derivatives with different Ring B analogues.  
The toxicity of aminocoumarins is thought to be due to the 3-amino-4,7-
dihydroxycoumarin moiety (Ring B). Therefore, we focussed in developing methods to 
exchange the natural Ring B by less toxic analogues.  
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II. MATERIALS AND METHODS 
II.1. Microbiology methods 
II.1.1. Microorganisms 
 
The bacterial strains used or constructed during this study are listed in Table II.1. 
 
Table II.1: Microorganisms. 
Strains Relevant genotype, description, or properties Reference 
   
E. coli   
K-12 MG1655  17
XL1 Blue general cloning host; recA1, endA1, gyrA96, thi-1, 
hsdR17, supE44, relA1, lac[F', proAB, lacIq, ZΔM15, 
Tn10]; Tetr 
19
Stratagene 
ET12567 DNA methylase negative strain; dam-13::Tn9, dcm-
6, hsdM; Tetr, Cmr 
71
BL21(DE3)/pLysS host strain for heterologous gene expression; F-, 
ompT, hsdSB(rB- mB-), gal, dcm, (DE3)pLysS; Cmr 
Novagen
BW25113 K-12 derivative; ΔaraBAD, ΔrhaBAD 27
JW0585-2 K-12 derivative; ΔentC; Kmr  8
JW5503-1 K-12 derivative; ΔtolC; Kmr  8
JW5195-1 K-12 derivative; ΔtonB; Kmr  8
JW3605-1 K-12 derivative; ΔrfaP; Kmr 8
SA-101 K-12 derivative; ΔtolC, ΔentC; aac(3)IV; Kmr, Aprr This study
SA-102 K-12 derivative; ΔtonB, ΔentC; aac(3)IV; Kmr, Aprr This study
SA-103 K-12 derivative; ΔtonB, ΔtolC; aac(3)IV; Kmr, Aprr  This study
SA-104 K-12 derivative; ΔtonB, ΔtolC, ΔentC; aac(3)IV; 
aadA; Kmr, Aprr, Strr 
This study
SA-105 K-12 derivative; ΔrfaP, ΔentC; aac(3)IV; Kmr, Aprr This study
SA-106 K-12 derivative; ΔrfaP, ΔtolC; aac(3)IV; Kmr, Aprr This study
SA-107 K-12 derivative; ΔrfaP, ΔtolC, ΔentC; aac(3)IV; 
aadA; Kmr, Aprr, Strr 
This study
   
Streptomyces coelicolor   
M512 S. coelicolor M145 derivative; ΔactII-ORF4, ΔredD, 
SCP1-, SCP2- 
38
M1154 S. coelicolor M145 derivative; Δact, Δred, Δcpk, 
Δcda, rpoB[C1298T], rpsL[A262G] 
45
M512(clo-BG1) S. coelicolor M512 containing cosmid clo-BG1; Kmr 31
M512(clo-SA2) S. coelicolor M512 containing cosmid clo-SA2; Kmr This study
M512(cloSA4) S. coelicolor M512 containing cosmid clo-SA4; Kmr This study
M1154(clo-SA2) S. coelicolor M1154 containing cosmid clo-SA2; Kmr This study
M512(clo-SA2)/pSA11 S. coelicolor M512 containing cosmid clo-SA2 and 
plasmid pSA11; Kmr, Tsrr  
This study
M1154(clo-SA2)/ 
pSP1261110 
S. coelicolor M1154 containing cosmid clo-SA2 and 
plasmid pSP1261110; Kmr, Tsrr 
This study
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II.1.2. Culture media 
 
Unless otherwise stated, the media were prepared with distilled water and autoclaved for 
20 min at 121°C. All the recipes for the media are given for 1 l of final volume. When 
necessary, supplementary components like antibiotics or other heat labile substances, 
sterilized by filtering through 0.22 µm pore sized filters, were added to the sterile media. 
Culture media were stored at RT or 4°C. 
 
Culture media for E. coli 
LB (Luria-Bertani) medium70 
NaCl 10.0 g
Tryptone 10.0 g
Yeast extract 5.0 g
 
Components were dissolved in 1 l water, adjusted to pH 7.0 and sterilized by autoclaving. 
 
Mueller-Hinton agar (Roth)  
Mueller-Hinton agar 38.0 g
 
Components were dissolved in 1 l water and sterilized by autoclaving. 
 
SOB medium 
Tryptone 20.0 g
Yeast extract 5.0 g
NaCl 0.5 g
 
Components were dissolved in 1 l water and sterilized by autoclaving.  
 
Culture media for Streptomyces 
TSB (Tryptone Soya Broth) medium59 
Tryptone Soya Broth 30.0 g
 
Components were dissolved in 1 l water and sterilized by autoclaving. 
 
MS (Mannitol Soya flour) Agar59 
Mannitol 20.0 g
Soya flour 20.0 g
Agar 20.0 g
 
The mannitol was dissolved in 1 l tap water and 100 ml each poured into flasks containing 
2 g agar and 2 g soya flour. The medium was sterilized twice (115°C, 15 min) by 
autoclaving with moving of the media between the two runs. 
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GYM medium105 
Glucose 4.0 g
yeast extract 4.0 g
Malt extract 10.0 g
Peptone  1.0 g
NaCl 2.0 g
 
Ingredients were dissolved in 1 l water, adjusted to pH 7.2 with NaOH and sterilized by 
autoclaving. 
 
Corn starch medium (Clorobiocin preculture medium)72 
Corn starch 10.0 g
Peptone  10.0 g
Meat extract 5.0 g
 
Ingredients were dissolved in 1 l water, adjusted to pH 7.0 and sterilized by autoclaving. 
 
Distillers solubles medium (clorobiocin production medium)72 
Distillers' solubles 48.0 g
Glucose 12.0 g
CoCl2  6 H2O 24 mg
CaCO3 6.0 g
 
(NH4)2SO4 (16%) 13 ml
Glucose (25%) 100 ml
 
Distillers' solubles, glucose and cobalt chloride were dissolved in 887 ml water and 
adjusted to pH 7.8. After adding of calcium carbonate the medium was sterilized by 
autoclaving. After autoclaving sterile ammonium sulphate and glucose solutions were 
added. 
 
CDM medium (novobiocin production medium)60 
tri-sodium citrate  2 H2O 6.0 g
L-proline 6.0 g
K2HPO4 · 3 H2O 2.0 g
(NH4)2SO4 1.5 g
NaCl 5.0 g
 
MgSO4  7 H2O 2.05 g
CaCl2  2 H2O 0.4 g
FeSO4  7 H2O 0.2 g
ZnSO4  7 H2O 0.1 g
 
Glucose (30%) 100 ml
 
The Ingredients up to NaCl were dissolved in 900 ml water and adjusted to pH 7.2. After 
adding of MgSO4, CaCl2, FeSO4 and ZnSO4 the medium was again adjusted to pH 7.2 and 
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sterilized by autoclaving. The glucose solution was also sterilized by autoclaving and 
added afterwards to the medium. 
 
YEME (Yest Extract Malt Extract) medium (protoplast transformation)59 
Sucrose 340.0 g
Glucose 10.0 g
Peptone 5.0 g
Yeast extract 3.0 g
Malt extract 3.0 g
 
MgCl2 (2.5 M) 2 ml
Glycine (20%) 25 ml
 
Ingredients were dissolved in 1 l water and sterilized by autoclaving. After autoclaving 
sterile MgCl2 and glycine solutions were added. 
 
R5 medium 
Sucrose 103.0 g
MgCl2  6 H2O 10.1 g
Glucose 10.0 g
TES 5.7 g
Yeast extract 5.0 g
K2SO4 0.25 g
Casaminoacids 0.1 g
Trace elements solution 2.0 ml
 
CaCl2  2 H2O (1 M) 20 ml
L-Prolin (20%) 15 ml
KH2PO4 (0.5%) 10 ml
 
The ingredients were dissolved in 1 l water and adjusted to pH 7.2 and sterilized by 
autoclaving. The three supplementary solutions were also sterilized by autoclaving and 
added afterwards to the medium. For the preparation of agar plates 23 g agar was added 
after adjusting to pH 7.2. For the preparation of soft agar only 6 g agar were added. 
Ingredients for the trace elements solution were dissolved in 1 l water and sterilized by 
autoclaving. 
 
 
II.1.3. Growth and preservation of microorganisms 
 
E. coli strains 
E. coli strains were routinely cultivated in liquid or on solid LB medium with appropriate 
antibiotics at 37°C overnight (18 h). Standard methods for cultivation were performed as 
described by Sambrook and co-workers100.  
Trace elements solution (for 1 l) 
FeCl3  6 H2O 200 mg
ZnCl2 40 mg
CuCl2  2 H2O 10 mg
MnCl2  4 H2O 10 mg
Na2B4O6  10 H2O 10 mg
(NH4)6Mo7O24  4 H2O 10 mg
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Stocks of E. coli strains for long term storage were prepared by mixing 800 µl of overnight 
culture with 400 µl sterile glycerol solution (80% in distilled water) and stored at -70°C. 
 
Streptomyces strains 
Standard methods for cultivation were performed as described by Kieser and co-workers59. 
For antibiotic production in batch fermentation, Streptomyces strains were routinely pre-
cultivated in liquid TSB medium (BD Bioscience) with appropriate antibiotics at 30°C for 2-
3 days using baffled Erlenmeyer flasks with a steel spring. The cultivation was continued in 
distillers' solubles, GYM or CDM medium for antibiotic production at 30°C for 5-8 days. 
For preparation of stocks of Streptomyces strains for long-term storage as frozen 
mycelium, 1 ml of 2-3 days old TSB culture was harvested by centrifugation, the cells were 
resuspended in 0.5 ml 20% glycerol and stored at -70°C. 
For long term storage as spore suspensions, Streptomyces strains were spread on MS or 
R5 agar and incubated at 30°C for about 1-2 weeks until dense and matured sporulation 
was observed. 6 ml Tween® 20 (0.1%) were added to each plate and the spores scraped 
off into suspension with a sterile cotton bud. The spore suspension was poured into a 
falcon tube, vortexed and separated from the mycelium by passing through sterile cotton 
wool. After centrifugation (4000 rpm, 10 min, 4°C) spores were resuspended in 0.5 ml 
glycerol (20%) and stored at -70°C. 
 
 
II.1.4. Antibiotic solutions 
 
For stock solutions, antibiotics were dissolved in sterile distilled water (unless otherwise 
stated) and kept at –20°C. The aqueous solutions were sterilized by filtration (pore size 
0.22 µm). For antibiotic selection, the required antibiotics were added to the media in 
appropriate concentrations. 
 
Antibiotic Resistance gene Final concentration 
in the media (µg/ml)  
Stock solution  
(mg/ml) 
    
Apramycin acc(3)IV 50 50 
Carbenicillin bla 100 100 
Chloramphenicol cat 25 25 (ethanol) 
Kanamycin neo 50 50 
Streptomycin aadA 10 10 
Tetracycline tet 12 12 (ethanol) 
Thiostreptone tsr 25 50 (DMSO) 
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II.2. Molecular biology methods 
 
Standard methods for DNA isolation and manipulation were performed as described by 
Sambrook and co-workers100 and Kieser and co-workers59.  
 
II.2.1. Vectors and constructs used in this study 
 
Cloning and expression vectors used for this study and the constructs generated during 
this work are listed in Table II.2. 
 
Table II.2: Vectors and constructs. 
Plasmids / 
Cosmids 
Description and Properties Reference / 
Source
   
Plasmids  
pJ201 pUC origin; Kmr DNA2.0  
pUWL201 E. coli-Streptomyces shuttle vector; ermE* promoter; pIJ101 
origin; Ampr, Tsrr 
28
pUG019 pBlueskript SK(-) derivative; aac(3)IV; Ampr 31
pQE70 expression vector; C-terminal (His)6-Tag; T5-promotor; ColE1 
origin; Ampr 
Qiagen
pET22b expression vector; C-terminal (His)6-Tag; f1 origin; Ampr Novagen
pREP4 lac repressor plasmid; p15Aori; Kmr Qiagen
pBR322 origin; Ampr, Tetr 100
pIJ790 λ-RED (gam, bet, exo), cat, araC, rep101ts 47
pIJ778 pBlueskript SK(-) derivative; aadA; Strr 47
pIJ773 pBlueskript SK(-) derivative; aac(3)IV, oriT; Aprr 47
pSH2 pUWL201 derivative containing simL; XbaI-HindIII restriction 
sites; Ampr, Tsrr 
47
pJJM301 pQE70 derivative containing dhbE; SphI-BamHI restriction sites; 
Ampr 
75
pET11cSaparC pET11c derivative containing parC; restriction sites; pBR322 
origin; Ampr 
Novagen
pET11cSaparE pET11c derivative containing parC; restriction sites;  pBR322 
origin; Ampr 
Novagen
pSP1261110 pUWL201 derivative containing dhbA, dhbC, dhbE, dhbB; 
EcoRV restriction sites; Ampr, Tsrr 
89
pSA07 pET22b derivative containing parC from pET11c-SaparC; NcoI-
XhoI restriction sites; Ampr 
This study
  pSA08 pET22b derivative containing parC from pET11c-SaparE;  NdeI-
XhoI restriction sites; Ampr 
This study
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II.2.2. DNA isolation 
 
Unless otherwise described, buffers and solutions were prepared with distilled water, 
autoclaved, and stored at room temperature. 
 
Alkaline lysis for plasmid and cosmid isolation from E. coli 
Miniprep solution 1 
Tris-HCl 50 mM
EDTA 10 mM
RNase A 100 µg/ml
 
Miniprep solution 2 
NaOH 0.2 M
SDS 1%
 
Miniprep solution 3 
Potassium acetate·pH 5.5 3 M
 
Tris-HCl and EDTA of solution 1 were dissolved in water and adjusted to pH 8.0. After 
autoclaving RNase A was added. Solution 3 was adjusted to pH 4.8 and stored at 4°C. 
 
Alkaline-lysis method was used to isolate recombinant plasmids from E. coli. 2 ml of 
culture were centrifuged (13000 rpm, 5 min, 4°C) and the pellet resuspended in 250 µl 
miniprep solution 1 by vortexing. 250 µl miniprep solution II were added, mixed by 
inversion and 5 min incubated at room temperature. The suspension was mixed with 250 
pSA09 pQE70 derivative containing parC from pET11c-SaparC; SphI-
BglI restriction sites; Ampr 
This study
  pSA10 pQE70 derivative containing parE from pET11c-SaparE; SphI-
BglI restriction sites; Ampr 
This study
pSA11 pUWL201derivative containing a synthetic ubiC/pobA DNA 
fragment; HindIII-SpeI restriction sites; Ampr, Tsrr 
This study
   
Cosmids  
clo-BG1 SuperCos1 derivative containing the clorobiocin biosynthetic 
gene cluster; oriT, tet, attP, int ΦC31; Kmr 
31
clo-SA1 clo-BG1 derivative; cloQ replaced by aac(3)IV resistance 
cassette; Aprr, Kmr 
This study
clo-SA2 clo-BG1 derivative; ΔcloQ; Kmr This study
clo-SA3 clo-BG1 derivative; cloHIJK replaced by aac(3)IV resistance 
cassette; Aprr, Kmr 
This study
clo-SA4 clo-BG1 derivative; ΔcloHIJK; Kmr This study
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µl miniprep solution 3, incubated for 5 min on ice and centrifuged (13000 rpm, 10 min, 
4°C). The supernatant was transferred into a fresh tube, mixed with 400 µl Rotiphenol® 
(Roth) by vortexing and centrifuged (13000 rpm, 5 min, 4°C). The supernatant was 
transferred into a fresh tube, 460 µl isopropanol added and mixed by inversion, and the 
DNA precipitated by centrifugation (13000 rpm, 30 min, 4°C). The pellet was washed with 
500 µl ethanol (70%), air dried and resuspended in 20 µl Tris-HCl buffer (10 mM). 
 
Eckhard-Lysis for fast plasmid isolation and test from E. coli colonies 
Eckhardt gel 
TAE buffer (1x)  
(see II.2.5) 
125 ml
SDS 0.25 g
Agarose 1.25 g
 
Eckhardt buffer 
Sucrose 6.25 g
Ficoll 400 0.75 g
TEA buffer (1x) 25 ml
Bromphenol blue 0.01%
 
To 1 ml of Eckhardt buffer 1 µl RNase A (100 mg/ml) and 5 mg lysozyme were added. 
 
Single colonies were picked with toothpicks and rubbed into 17 µl Eckhardt buffer 
(microplates are suitable). Samples were put directly on the Eckhardt gel and run for the 
first 15 min with 20 V and after that with 90 V. Before staining with ethidium bromide, the 
SDS was removed by washing the gel with distilled water.  
 
Plasmid isolation from Streptomyces 
Miniprep solution 1  
Glucose 50 mM
Tris-HCl 25 mM
EDTA 10 mM
RNase A 100 µg/ml
Lysozyme 4 mg/ml
 
Tris-HCl and EDTA of solution 1 were dissolved in water and adjusted to pH 8.0. After 
autoclaving RNase A and lysozyme were added. 
 
Miniprep solution 2  
NaOH 0.2 M
SDS 1%
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Miniprep solution 3 
Potassium acetate 5 M
 
Solution 3 was adjusted to pH 4.8 and stored at 4°C. 
 
Alkaline-lysis was used to isolate recombinant plasmids from Streptomyces. For isolation 
of plasmids from Streptomyces 500 µl miniprep solution 1 for Streptomyces was added 
after the resuspension of the pellet in 1 ml miniprep solution 1 for E. coli. The suspension 
was incubated at 37°C for 60 min with inversion of the tubes every 10 min. The procedure 
was continued as described under “Alkaline lysis for plasmid and cosmid isolation from E. 
coli” 
 
 
II.2.3. DNA quantification and  manipulation with enzymes 
 
DNA quantification 
DNA was quantified by comparing the fluorescence intensity with the GeneRulerTM 1 kb 
DNA ladder (Fermentas) on an agarose gel after staining with ethidium bromide.  
 
Restriction digest 
Restriction of DNA with endonucleases was performed according to the instructions 
provided by manufacturers (Amersham; New England Biolabs). 
 
Ligation 
DNA ligation was performed by using 1U T4-DNA ligase (Amersham), 1x ligation buffer 
and the mixture of insert and linearized vector at a 1:1 ratio in a total volume of 10 µl. The 
mixture was incubated at 4°C over night. 
 
Dephosphorylation 
This reaction avoids intramolecular ligation by dephosphorylation of the 5'-end of DNA. 0.2 
U alkine phosphatase (Amersham), 1x alkaline phosphatase buffer and DNA were 
incubated for 1 h at 37°C. 
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II.2.4. PCR amplification of DNA 
 
PCR amplification was performed with an iCycler® PCR-System (Bio-Rad). The 
oligonucleotide primers, listed in Table II.3, were purchased to MWG-Biotech. PCR 
amplifications for plasmid construction and gene inactivation by PCR targeting47 were 
performed with the Expand High Fidelity PCR System (Roche) and the Phusion 
polymerase (New England BioLabs). Colony PCR was performed with Taq-DNA 
polymerase (New England BioLabs).  
 
PCR products were purified using a High Pure PCR Product Kit (Roche) and 2 µl analysed 
on an agarose gel as described in section II.2.5. 
 
Table II.3: Oligonucleotides. 
Name Sequence (5'-3') Restriction 
sites 
 
Primers for cloQ inactivation 
cloQ_f GGC GCG CCC ATT GCT CAC CGT CTT ACC GAC ACC GTC 
CTT ATT CCG GGG ATC TCT AGA TC 
XbaI 
cloQ_r TCC CAT GGT CGA TTC CGT GTG TTG GTG AAG TGC GCG 
CAG ACT AGT CTG GAG CTG CTT C 
SpeI 
   
Primers for cloHIJK inactivation (resulting in cosmid clo-SA3 / clo-SA4) 
cloHIJK_f GTA TGT TCC AAT GGC ATG GAG ACT TAA GGG GGA AGT 
TTG TCT AGA ATT CCG GGG ATC CGT CGA CC 
XbaI 
cloHIJK_r GTG CTC CGG TCC GTG GTC CTT GTT CGC CAC CAG TGA 
CTA ACT AGT TGT AGG CTG GAG CTG CTT C 
SpeI 
   
Primers for construction of plasmid pSA07 
parC_f_NcoI C ATG CCA TGG TGA GTG AAA TAA TTC AAG ATT TAT CA NcoI 
parC_f_XhoI CCG CTC GAG GCT AAT ATA CAT GTC TAT TAC TTC AC XhoI 
   
Primers for construction of plasmid pSA08 
parE_f_NdeI GG GAA TTC CAT ATG AAT AAA CAA AAT AAT TAT TCA 
GAT GAT TCA ATA 
NdeI 
parE_f_XhoI CCG CTC GAG GAT TTC CTC CTC ATC AAA TTG A XhoI 
   
Primers for construction of plasmid pSA09 
parC_f A AAG GCA TGC ATA GTG AAA TAA TTC AAG ATT TAT CAC 
TT 
SphI 
parC_r GGA AGA TCT GCT AAT ATA CAT GTC TAT TAC TTC AC BglII 
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Primers for construction of plasmid pSA10 
parE_f A AAG GCA TGC ATA ATA AAC AAA ATA ATT ATT CAG ATG 
ATT CA ATA 
SphI 
parE_r GGA AGA TCT GAT TTC CTC CTC ATC AAA TTG ATC BglII 
 
Primers for construction of the E. coli mutant strains 
entC_f T CAT TAT TAA AGC CTT TAT CAT TTT GTG GAG GAT GAT 
ATG att ccg ggg atc cgt cga cc 
 
entC_r C CGG CCA GCG GGT GAA TGG AAT GCT CAT CCT CGC TCC 
TTA tgt agg ctg gag ctg ctt c 
 
tolC_f G ATC GCG CTA AAT ACT GCT TCA CCA CAA GGA ATG CAA 
ATG att ccg ggg atc cgt cga cc 
 
tolC_r A CGT TCA GAC GGG GCC GAA GCC CCG TCG TCG TCA TCA 
tgt agg ctg gag ctg ctt c 
 
 
Primers for testing of the E. coli mutant strains by colony PCR 
entC_T1 GAG TTG CAG ATT GCG TTA CC  
entC_T2 CGT CAG AAT GTC GGT CAG CG  
tolC_T1 CAT TAA CGC CCT ATG GCA CG  
tolC_T2 GAA TAG AGG ATG GCT GGT CG  
tonB_T1 TGT CTT TGT TAA GGC CAT GC  
tonB_T2 TTG GGC AAC GCT ATA AAG CG  
rfaP_T1 GCC CCA GCC ATG CAT TAT CC  
rfaP_T2 AGT CGC CAT TGC GAA TGG CC  
 
 
II.2.5. Agarose gel electrophoresis of DNA 
 
50x TAE buffer 
Tris base 2 M
EDTA 0.05 M
Glacial acetic acid 57.1 ml/l
 
The pH was adjusted to 8.0 with glacial acetic acid. 
 
Loading buffer 
Glycerol 49.75%
Tap water 50%
Bromphenol blue 0.25%
 
Ethidium bromide solution 
Ethidium bromide 1 mg/l
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1% agarosese gels (Biozym) were prepared with 1x TAE buffer to separate DNA 
fragments between 0.25 and 10 kb. As marker, the GeneRulerTM 1 kb DNA ladder 
(Fermentas) was used. Gels were run in 1x TAE buffer, stained with ethidium bromide 
solution for 15 min and analysed with UV light (312 nm) with an Eagle Eye II System 
(Stratagene) or a gel documentation system from Biostep equipped with a Argus X1 
software.  
 
DNA fragments were isolated from agarose gels using a NucleoSpin® 2 in 1 extraction kit 
(Macherey-Nagel) according to the protocol supplied by the manufacturer.   
 
                                                                                              
II.2.6. Introduction of DNA in E. coli and Streptomyces 
 
Electroporation of E. coli cells 
Preparation of electro-competent E. coli cells: 
100 ml LB medium was inoculated with 1 ml E. coli overnight culture and cultivated at 
37°C until the OD600 reached 0.6. The cells were harvested by centrifugation (5000 rpm, 
10 min, 4°C) and washed twice with 30 ml ice-cold glycerol solution (10%). The pellet was 
suspended in the remains of the discarded supernatant. The competent cells were used 
immediately or stored in 50 µl aliquots at -70°C. 
 
Electroporation: 
3 µl DNA (about 100 ng) were mixed with 50 µl competent cells. The mixture was 
transferred into an ice-cold electroporation cuvette (0.2 cm) and electroporation was 
carried out with 2.5 kV using an electroporator (BioRad). The optimal time constant is 4.5 – 
5.0 ms. 500 µl cold LB medium was immediately added to the electroporated cells. After 1 
h incubation of the cells at 37°C, 200 µl were spread on LB agar containing an appropriate 
antibiotics. The agar plates were incubated overnight at 37°C.  
 
PEG-mediated protoplast transformation of Streptomyces 
The following sterile solutions were prepared separately before mixing the buffers. The 
buffers were stored at -20°C. 
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 Stock solution Amount 
   
P(protoplast)-buffer   
Sucrose 12% 85.5 ml 
TES 0.25 M, pH 7.2 10.0 ml 
MgCl2 · 6 H2O 1 M 1.0 ml 
K2SO4 140 mM 1.0 ml 
KH2PO4 40 mM 1.0 ml 
CaCl2 · 2 H2O 250 mM 1.0 ml 
Trace element solution (see R5 medium) 0.2 ml 
distilled water  to 100 ml 
   
T(transformation)-buffer   
PEG 1000 50% 5.0 ml 
Sucrose 25% 1.0 ml 
CaCl2 · 2 H2O 5 M 1.0 ml 
Tris-maleate 0.5 M, pH 8.0 1.0 ml 
K2SO4 140 mM 0.1 ml 
KH2PO4 40 mM 0.1 ml 
MgCl2 · 6 H2O 1 M 0.1 ml 
Trace element solution (see R5 medium) 0.03 ml 
distilled water  to 10 ml 
 
Protoplast preparation: 
20 µl spores were added to 1 ml TSB medium and incubated for 5 min at 50°C. After 2 h 
incubation at 30°C, 50 ml YEME medium with MgCl2 and glycin were inoculated and 
cultivated for 2 d. The mycelium was harvested by centrifugation (5000 rpm, 10 min, 4°C) 
and washed twice with 20 ml sucrose solution (10.3%). The pellet was resuspended in 
sterile filtered lysozyme solution (4 ml P-buffer for 1 g cell pellet) and incubated for 30 – 60 
min at 30°C with gentle moving. Protoplast formation was identified by microscopy and the 
reaction was stopped by incubation on ice. 10 ml ice-cold P buffer were added, gently 
mixed with the protoplasts by pipetting and filtered through cotton wool. After centrifugation 
(3000 rpm, 10 min, 4°C) the supernatant was discarded and the pellet carefully 
resuspended in the remaining liquid. Protoplasts were used immediately for transformation 
or stored in 100 µl aliquots at -70°C. 
 
Protoplast transformation: 
Before transformation, plasmid DNA was isolated from the DNA-methylation deficient 
strain E. coli ET12567. 10 µl (about 15 µg) plasmid DNA were added to 100 µl protoplasts 
and 100 µl P buffer. The suspension was mixed carefully by pipetting. The tube was 
inverted several times after adding of 500 µl T buffer and incubated for 1 min at room 
temperature. 100 µl, 200 µl and 400 µl of this suspension were mixed with 3 ml melted R5 
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soft agar each and poured on R5 agar plates. After 24 h incubation at 30°C the plates 
were overlaid with 3 ml R5 soft agar including the required antibiotics for selection. The 
incubation was continued for 7 d. 
 
 
II.2.7 Construction and heterologous expression of the plasmid pSA11 
 
Design of the synthetic gene operon for 3,4-DHBA biosynthesis 
The nucleotide sequences of the genes pobA coding for a 4-hydroxybenzoate hydroxylase 
from Corynebacterium cyclohexanicum (GenBank AB210281) and ubiC coding for a 
chorismate pyruvate-lyase from Escherichia coli 536 (GenBank NC_008253) were 
redesigned using the codon preference of S. coelicolor M512 (DNA2.0 Gene Designer 
Software). The two genes were linked by translational coupling and flanked by SpeI and 
HindIII restriction sites. The DNA fragment was synthesized by DNA2.0 company 
(California, USA) and provided in the vector pJ201. This nucleotide sequence of the 
synthetic ubiC/pobA DNA fragment has been listed in Figure III.4. 
 
Cloning of the synthetic gene operon in an expression vector 
The synthetic ubiC/pobA fragment was isolated from the pJ201 vector (DNA2.0) by 
restriction digest with SpeI and HindIII and cloned into pUWL201 which contains the 
constitutive ermE* promoter for foreign gene expression. Transformation of pSA11 into the 
integration mutant S. coelicolor M512(clo-SA2) was carried out by PEG-mediated 
protoplast transformation (II.2.6). Transformed colonies appeared after 5 d at 30 °C. 
 
 
II.2.8 Construction and heterologous expression of cosmid clo-SA2 
 
In cosmid clo-BG1, cloQ was replaced by RED/ET-mediated recombination with an 
apramycin-resistance (aac(3)IV) cassette that was flanked by XbaI and SpeI recognition 
sites. For replacement of cloQ, the cassette was generated by PCR using pUG019 as 
template and the primers cloQ_f and cloQ_r (Table II.3). PCR amplification was performed 
in 50 µl volume with 100 ng template, 0.25 mM dNTPs, 50 pmol of each primer, and 5% 
(v/v) DMSO with the Expand High Fidelity PCR system (Roche): denaturation at 94 °C for 
2 min, then 10 cycles with denaturation at 94 °C for 45 s, annealing at 50 °C for 45 s, and 
elongation at 72 °C for 90 s, followed by 15 cycles with annealing at 55 °C for 45 s, and 
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the last elongation step at 72 °C for 5 min. The PCR product was introduced by 
electroporation into E. coli BW25113/pIJ790 harboring cosmid clo-BG1. The resulting 
modified cosmid clo-SA1 was isolated, transformed into the nonmethylating strain E. coli 
ET12567, reisolated, and digested with XbaI and SpeI to remove the apramycin-resistance 
cassette. Religation overnight at 4 °C gave the cosmid clo-SA2.  
The cosmid clo-SA2 isolated from E. coli ET12567 was introduced into S. coelicolor M512 
by PEG-mediated protoplast transformation. Clones resistant to kanamycin were selected. 
Feeding experiments were carried out by addition of 1 mg Ring A (3-dimethylallyl-4-
hydroxybenzoic acid) dissolved in 100 µl ethanol to 80 ml S. coelicolor M512(clo-SA2) 
culture in distillers` solubles medium.  
For mutasynthesis experiments, 3 mg of the respective catechol compounds were 
dissolved in 100 µl ethanol and added to 80 ml of the culture of the cloQ defective strain S. 
coelicolor M512(clo-SA2) in distillers` solubles medium one day after inoculation. After 5-8 
days cultivation at 30 °C and 210 rpm, the cultures were extracted and analyzed by HPLC 
described below.  
 
 
II.2.9. Construction and heterologous expression of cosmid clo-SA4 
 
In cosmid clo-BG1 cloHIJK was replaced by RED/ET-mediated recombination with an 
apramycin-resistance (aac(3)IV) cassette that was flanked by XbaI and SpeI recognition 
sites. For replacement of cloHIJK, the cassette was generated by PCR by using pIJ773 as 
template and the primers cloHIJK_f and cloHIJK_r (Table II.3). PCR amplification was 
performed in 50 µl volume with 100 ng template, 0.25 mM dNTPs, 50 pmol of each primer, 
and 5% (v/v) DMSO with the Expand High Fidelity PCR system (Roche): denaturation at 
94 °C for 2 min, then 10 cycles with denaturation at 94 °C for 45 s, annealing at 50 °C for 
45 s, and elongation at 72 °C for 90 s, followed by 15 cycles with annealing at 55 °C for 45 
s, and the last elongation step at 72 °C for 5 min. The PCR product was introduced by 
electroporation into E. coli BW25113/pIJ790 harboring cosmid clo-BG1. The resulting 
modified cosmid clo-SA3 was isolated, transformed into the nonmethylating strain E. coli 
ET12567, reisolated, and digested with XbaI and SpeI to remove the apramycin-resistance 
cassette. Religation overnight at 4 °C gave the cosmid clo-SA4.  
The cosmid clo-SA4 isolated from E. coli ET12567 was introduced into S. coelicolor M512 
by PEG-mediated protoplast transformation. Clones resistant to kanamycin were selected. 
Feeding experiments were carried out by addition of 2 mg Ring B (3-amino-4,7-dihydroxy-
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8-methyl-coumarin) dissolved in 100 µl ethanol to 80 ml S. coelicolor M512(clo-SA4) 
culture in distillers` solubles medium. After 5-8 days cultivation at 30 °C and 210 rpm, the 
cultures were extracted and analyzed by HPLC as described under II.4.1.  
 
 
II.2.10. Generation of E. coli mutants 
 
E. coli double and triple mutants were generated from E. coli K-12 MG1655 mutants 
obtained from the Keio collection. The gene entC was replaced in E. coli JW5195-1/pIJ790 
and JW5503-1/pIJ790 using RED/ET-mediated recombination. An apramycin resistance 
cassette (acc(3)IV) was amplified from plasmid pIJ773. The primers entC_f and entC_r 
used for PCR amplification are listed in Table II.3. The gene tolC was replaced in E. coli 
JW5195-1/pIJ790 using RED/ET-mediated recombination. For this purpose, a 
streptomycin resistance cassette (aadA) was amplified from plasmid pIJ778 using the 
primer pair tolC_f and tolC_r (Table II.3). The genotype of the resulting mutants was 
confirmed by PCR with chromosomal DNA. 
 
 
II.3. Biochemistry methods 
II.3.1. Assay compounds, enzymes, DNAs and chemicals 
 
Reference compounds  
Novobiocic acid Isolated from S. spheroides AM1T2 
Novobiocin Sigma-Aldrich 
Clorobiocin A. Maxwell (John Innes Centre Norwich, UK) 
Coumermycin A1 Sigma-Aldrich 
Simocyclinone D8 H.-P. Fiedler (University of Tübingen, Germany). 
  
Ring B 
(3-amino-4,7-dihydroxy-8-methyl-coumarin) 
Pharmacia & Upjohn, Inc. (Kalamazoo, MI) 
Ring A 
(3-Dimethylallyl-4-hydroxybenzoic acid) 
Obtained by hydrolysis of novobiocin 
Catechol compounds Sigma-Aldrich 
Enterobactin Sigma-Aldrich 
  
Enzymes  
E. coli DNA gyrase  Inspiralis (Norwich, UK) 
E. coli DNA topoisomerase IV Inspiralis (Norwich, UK) 
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S. aureus DNA gyrase Inspiralis (Norwich, UK) 
  
DNAs  
relaxed pBR322 DNA Inspiralis (Norwich, UK) 
kDNA (from Crithidia fasciculate) Inspiralis (Norwich, UK) 
  
Chemicals  
Potassium glutamate Fluka 
Sodium glutamate Sigma-Aldrich 
KCl Sigma-Aldrich 
NaCl Sigma-Aldrich 
2,2'-bipyridyl Sigma-Aldrich 
2,3,5-triphenyltetrazolium chloride Roth 
 
 
II.3.2. General methods for protein expression and purification 
 
Overexpression and purification of His6-Tag proteins from E. coli were carried out as 
described by the user manual of Qiagen “A handbook for high level expression and 
purification of 6x His-tagged proteins”. The buffers were prepared with distilled water, 
autoclaved, filtered through 0.2 µm pore sized filters and stored at 4°C. If required, 
imidazol, β-mercaptoethanol, lysozyme, PMSF and DTT were added fresh before use. 
 
Lysis buffer 
Tris-HCl (pH 8.0) 50 mM
NaCl 500 mM
Glycerol 10%
Tween® 20 1%
Imidazol 20 mM
β-Mercaptoethanol 10 mM
Lysozyme 0.5 mg/ml
PMSF 0.5 mM
 
Washing buffer 
Tris-HCl (pH 8.0) 50 mM
NaCl 500 mM
Glycerol 10%
Imidazol 20 mM
β-Mercaptoethanol 10 mM
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Elution buffer 
Tris-HCl (pH 8.0) 50 mM
NaCl 500 mM
Glycerol 10%
Imidazol 250 mM
β-Mercaptoethanol 10 mM
 
Dialysis buffer 
Tris-HCl (pH 8.0) 25 mM 
NaCl 100 mM
DTT 2 mM
Glycerol 15%
 
 
II.3.3. Cloning, protein expression, and purification of S. aureus topoisomerase 
IV subunits ParC and ParE 
 
S. aureus RN4220 parC and parE (GenBank D67075) were PCR-amplified using plasmids 
pET11c-SaparC and pET11c-SaparE kindly provided by H. Hiasa (University of 
Minnesota) as a template. The primers ParC_f/ParC_r and ParE_f/ParE_r are listed in 
Table II.3. parC and parE were cloned into the SphI and BglII restriction sites of pQE70 
expression vector and transformed in E. coli BL21/pREP4 cells. For protein expression, 
cultures were grown at 37°C in 1 l of LB medium to OD600 = 0.7. 1 mM IPTG was added 
and growth continued for 4 h at 37°C. After centrifugation cell pellets were resuspended in 
25 ml lysis buffer and sonicated to release soluble proteins. Insoluble material was 
removed by centrifugation and the supernatant loaded onto a 5 ml His-TrapTM HP column 
(GE Healthcare) that had been equilibrated previously with washing buffer. The column 
was eluted with a linear gradient from 20 – 250 mM imidazole (30 min; 1 ml/min) and the 
eluates were dialyzed against the dialysis buffer. The final yields were 7 mg/l of ParC and 
5 mg/l of ParE, respectively. Absorbance at 280 nm was measured to calculate protein 
concentration. SDS polyacrylamide gel electrophoresis of the purified topoisomerase IV 
subunits revealed bands with apparent molecular weights of 96.2 kDa and 77.8 kDa, 
corresponding to ParC and ParE, respectively. S. aureus topoisomerases IV were 
reconstituted in vitro by mixing equimolar amounts of the subunits and incubation on ice 
for 10 min. 
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II.3.4. Cloning, protein expression, and purification of the AMP ligase DhbE 
 
The E. coli strain BL21(DE3)pLysS/pREP4 with the integrated plasmid pJJM301 was 
kindly provided by M. Marahiel (University of Marburg, Germany). For protein expression, 
cultures were grown at 37°C in 1 l of LB medium to OD600 = 0.7. 500 µM IPTG was added 
and growth continued for 3 h at 30°C. After centrifugation cell pellets were resuspended in 
12.5 ml lysis buffer and sonicated to release soluble proteins. Insoluble material was 
removed by centrifugation and the supernatant loaded onto a 5 ml His-TrapTM HP column 
(GE Healthcare) that had been equilibrated previously with washing buffer. The column 
was eluted twice with elution buffer and the eluates were dialyzed against the dialysis 
buffer. The final yields were 21 mg of purified protein DhbE of one litre culture. 
Absorbance at 280 nm was measured to calculate protein concentration. SDS 
polyacrylamide gel electrophoresis of the purified protein revealed a band with the 
apparent molecular weight of 59.9 kDa, corresponding to DhbE. DhbE was used in amide 
synthetase assays with the catechol substrat 2,3-dihydroxybenzoic acid as described 
under II.3.6. 
 
 
II.3.5. Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) and 
Coomassie staining 
 
 Stock solution Amount 
   
1 Stacking gel (4%)    
Distilled water  1192 µl 
Tris-HCl (pH 6.8) 0.5 M, pH 6.8 500 µl 
SDS 10% 20 µl 
Rotiphorese® Gel 30 30% 266 µl 
APS 10% 20 µl 
TEMED 100% 2 µl 
   
1 Running gel (12%)   
Distilled water  1848 µl 
Tris-HCl 1.5 M, pH 8.8 1000 µl 
SDS 10% 40 µl 
Rotiphorese® Gel 30 30% 1068 µl 
APS 10% 40 µl 
TEMED 100% 4 µl 
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Laemmli buffer (4x)   
Tris-HCl 1 M, pH 6.8 2.5 ml 
Glycerol 100% 4 ml 
SDS  0.8 g 
Bromphenol blue  0.4 mg 
ß-Mercaptoethanol 100% 2.0 ml 
Distilled water  ad 10 ml 
 
Electrophoresis buffer (10x) 
Tris base 30.3 g 
Gycine 144 g 
SDS 10.0 g 
Distilled water ad 1 l 
 
Fixing buffer 
Distilled water 70% 
Acetic acid 10% 
Methanol 20% 
 
Staining buffer 
Coomassie Brilliant 
Blue G-250 
0.25% 
Distilled water 45% 
Acetic acid 10% 
Methanol 45% 
 
Bleaching buffer 
Distilled water 45% 
Acetic acid 10% 
Methanol 45% 
 
The SDS-PAGE was carried out according to the method of Laemmli62. Sample and 
sample buffer were mixed in the ratio 3:1 (total volume 40 µl) and incubated for 3 min in 
boiling water (95°C). 4% and 12% polyacrylamide gels were used as stacking and running 
gels respectively. Gel electrophoresis was carried out at 100 V during the run in the 
stacking gel and later at 200 V using a Mini-PROTEAN II electrophoresis cell (BioRad). 
Proteins were stained with Coomassie Brilliant Blue G-250 solution for 15 min after 
treatment of the gels with fixing buffer for 5 min. The following bleaching of the gels was 
carried out with bleaching solution for 2 h. To determine protein sizes, 2 µl of protein 
marker (LMW Calibration Kit for SDS Electrophoresis, GE Healthcare) were used. 
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II.3.6. Amide synthetase assay 
 
The assay contained the listed components in a final volume of 100 µl. The acyl substrates 
are 3,4-dihydroxybenzoic acid, 2,3-dihydroxybenzoic acid, caffeic acid, 3,4-
dihydroxyphenylacetic acid, 3,4-dihydroxypropionic acid or 3,4-dihydroxymandelic acid, 
respectively. 
 
Acyl substrate 2 mM
Ring B 2 mM
ATP 5 mM
Mg2Cl 5 mM
Ascorbic acid 10 mM
Tris-HCl (pH 8.0) 100 mM
Acyl ligase 10 µg
 
The reaction was carried out for 45 min at 30°C and stopped by addition of 5 µl 1.5 M 
trichloroacetic acid. The reaction mixture was extracted with 100 µl ethyl acetate. The 
organic layer was used for analysis. After evaporation of the solvent and dissolution in 100 
µl methanol, the sample was analyzed by HPLC. A linear gradient from 60% to 100% 
solvent B (solvent A H2O/HCOOH 99:1; solvent B MeOH/HCOOH 99:1) over 30 min was 
used. UV detection was carried out at 330 nm. Novobiocic acid was used as standard.  
  
 
II.3.7. Topoisomerase IV decatenation assay 
 
New aminocoumarin compounds were obtained by metabolic engineering, mutasynthesis 
and chemoenzymatic synthesis as described previously. These compounds were 
dissolved in a small volume of dimethyl sulfoxide (DMSO) and the solutions were diluted 
with water to a final concentration of 5% DMSO. Topoisomerase IV activity was measured 
by using a decatenation assay that monitored the ATP-dependent unlinking of DNA 
minicircles from kDNA. 
 
Assay buffer 
HEPES-KOH (pH 7.5) 40 mM
Potassium glutamate 100 mM
Magnesium acetate 10 mM
DTT 10 mM
ATP 1.2 mM
Albumin 50 µg/ml
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Dilution buffer 
HEPES-KOH (pH 7.5) 40 mM
Potassium glutamate 100 mM
EDTA 1 mM
DTT 1 mM
Glycerol 40%
 
Stop buffer 
Sucrose 40%
Tris-HCl (pH 7.5) 100 mM
EDTA 100 mM
Bromphenol blue 0.25%
 
Topoisomerase IV decatenation assays (30 µl) were performed by incubating 200 ng of S. 
aureus topoisomerase IV or 2 U of E. coli topoisomerase IV and 200 ng kDNA with the 
indicated concentrations of the aminocoumarins in the assay buffer. The final DMSO 
concentration in the assay did not exceed 0.5% (v/v). The reactions were performed at 
37°C and terminated after 45 min by addition of an equal volume of stop buffer, followed 
by extraction with one volume of chloroform/iso-amyl alcohol (24:1). The aqueous phase 
was analyzed on 1% agarose gels for 4 h at 80 V in TAE and visualized after staining with 
ethidium bromide. The IC50 for inhibition of decatenation can be visually assessed as the 
concentration of compound which leads to a 50% reduction in the mini-circle band. IC50 
values are averages from at least two separate experiments. 
 
 
II.3.8. DNA gyrase supercoiling assay 
 
The same compounds as in the topoisomerase IV decatenation assays were tested. DNA 
gyrase activity was measured by a supercoiling assay that monitored the ATP-dependent 
conversion of relaxed pBR322 DNA to the supercoiled form. 
 
Assay buffer (5x) 
Potassium glutamate  3500 mM 
Tris-HCl (pH 7.5) 175 mM
KCl 120 mM
Mg2Cl 20 mM
DTT 10 mM
Spermidin 9 mM
ATP 6 mM
Albumin 0.5 mg/ml
Glycerol 32.5%
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Dilution buffer 
Tris-HCl (pH 7.5) 50 mM
KCl 100 mM
DTT 2 mM
EDTA 1 mM
Glycerol 50%
 
Assays (30 µl) were prepared by mixing 6 µl assay buffer (5x) with 0.5 µg of the relaxed 
pBR322 DNA, water and either 1 U of S. aureus or 1 U of E. coli DNA gyrase dissolved in 
6 µl of dilution buffer (5x). Reaction mixtures were incubated at 37°C for 45 min and 
terminated by adding 30 µl stop buffer (see II.3.7), followed by extraction with one volume 
(30 µl) chloroform/iso-amyl alcohol (24:1). Prior to agarose gel analysis, samples were 
subjected to a buffer exchange with 10 mM Tris-HCl (pH 8.0), performed by dialysis with 
MFTM-membrane filters (Millipore, 0.025 µm VSWP). For this purpose, membrane filters 
were cut into pieces and placed on the surface of the buffer solution in a petri dish. The 
aqueous phase of the assay mixtures was pipetted onto the floating membranes, and the 
petri dish was covered with a lid to avoid evaporation. After 3 h, the assay mixtures were 
removed from the membranes and mixed with 15 µl loading buffer (50% water, 49.75% 
glycerol, and 0.25% bromophenol blue). 20 µl of each sample were analysed by agarose 
gel electrophoresis as described under II.2.5. The IC50 for inhibition of the supercoiling can 
be visually assessed as the concentration of compound which leads to a 50% reduction in 
the supercoiling band. IC50 values are averages from at least two separate experiments. 
 
 
II.3.9. Agar diffusion tests 
 
Agar plates (40 ml medium) were prepared by adding 1 ml of a culture of the respective E. 
coli mutant (overnight culture in LB medium, OD600 1.2) (Table II.1) and 50 µM 2,2`-
bipyridyl in melted Mueller-Hinton agar (Roth). Different amounts of antibiotic, dissolved in 
15 µl methanol, were applied to paper disks of 7 mm of diameter. These disks were placed 
on the agar and the plates were incubated at 37 °C for 16 h. For visualization of living 
cells, plates were flooded with 5 ml of 0.5% aqueous 2,3,5-triphenyltetrazolium chloride 
(Roth), and after incubation for 10 min at 37°C the inhibition zones were determined. The 
minimal inhibitory concentration (MIC) was determined according to Wiegand and co-
workers123. 
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II.4. Analytical chemistry techniques  
II.4.1. Production and purification of novclobiocin 401 
 
S. coelicolor M512(clo-SA2)/pSA11 was precultivated in TSB medium (BD Bioscience) 
with 50 µg/ml thiostrepton for 3 days and then used to inoculate 40 flasks, each containing 
50 ml CDM production medium  with 50 µg/ml thiostrepton. The cultivation was carried out 
for 5 days at 30 °C and 210 rpm. The culture was adjusted to pH 4 with hydrochloric acid 
and extracted twice with an equal volume of ethyl acetate. The organic layer was 
evaporated to dryness. The residue was dissolved in methanol and purified by preparative 
HPLC with a linear gradient from 70% to 100% solvent B in solvent A over 36 min (solvent 
A H2O/HCOOH 99:1; solvent B MeOH: HCOOH 99:1).  
For analytic purposes, 1 ml bacterial culture was acidified with HCl to pH 4 and extracted 
with equal volume of ethyl acetate. After evaporation of the solvent, the residue was re-
dissolved in 100 µl methanol. 80 µl were analyzed by HPLC with a linear gradient from 
60% to 100% solvent B over 23 min. UV detection was carried out at 280 nm. 
 
 
II.4.2. HPLC analysis 
 
For HPLC analysis an Agilent 1100 system with ChemStation software was used. For 
analytical purpose, samples were analysed in a Multosphere RP18-5 column (250 x 4 mm, 
5 µm; Agilent) at a flow rate of 1 ml/min. For preparative HPLC analysis extracts were 
purified using a Multosphere column 120 RP18-5 (250 x 20 mm, 5 µm; C&S 
Chromatographie Service Düren, Germany) at a flow rate of 2 ml/min. For detailed 
information see II.4.1. 
 
 
II.4.3. LC-MS analysis 
 
For LC-ESI-MS analysis an electrospray ionization (ESI) mass spectrometer (LC/MSD 
Ultra Trap System XCT 6330; Agilent Technology) was used. Culture extracts were 
prepared as described under II.4.1. Samples were analysed on a Nucleosil 100-C18 
column (100 x 2 mm, 3 µm) at a temperature of 40 °C and a flow rate of 400 µl/min. A 
linear gradient of solvent A (H2O/HCOOH 99.9:0.1) and solvent B (methanol/HCOOH 
99.94:0.06) from 60% to 100% of solvent B over 20 min was used. UV detection was 
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carried out at 280 nm and authentic clorobiocin was used as a standard. ESI-MS detection 
of ions was performed in negative mode. High resolution ESI mass spectrometry was 
performed on a Bruker Apex IV, FT-ICR 7 Tesla mass spectrometer.  
 
 
II.4.4. NMR analysis 
 
For NMR analysis novclobiocin 401 was dissolved in CD3OD and NMR spectra were 
recorded on Varian Inova spectrometers. 1H NMR spectra were recorded at 600 MHz and 
13C NMR spectra were recorded at 125.7 MHz respectively. Chemical shifts in CD3OD are 
reported as δ values relative to respective solvent as an internal reference.
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III. RESULTS 
III.1. Generation and activity test of novclobiocin 401, a clorobiocin 
derivative containing the catechol moiety 3,4-dihydroxybenzoic 
acid 
 
III.1.1. Investigation of the substrate tolerance of different aminocoumarin acyl 
ligases for acyl substrates with catechol moieties 
 
The main aim of this study was the replacement of the genuine 3-dimethylallyl-4-
hydroxybenzoyl moiety (Ring A) of clorobiocin (Figure I.1) with an acyl moiety containing a 
catechol structure. We considered six different acids which contain catechol motifs (Figure 
III.1A). Previous mutasynthetic experiments aimed at the replacement of Ring A by other 
acyl groups, had shown that the success depends primarily on the acceptance of the acyl 
substrate by the aminocoumarin acyl ligase (or amide synthetase) enzyme that attaches 
the acyl moiety to the 3-amino group of the aminocoumarin moiety43, 4. The later 
biosynthetic steps, glycosylation and final tailoring steps, appeared not to be affected by 
modifications of the structure of the acyl moiety. We therefore tested the acceptance of the 
six acyl substrates with catechol motifs (Figure III.1A) by four different aminocoumarin 
acyl ligases from the biosynthetic gene clusters of novobiocin, clorobiocin, coumermycin 
A1, and simocyclinone D8 (NovL, CloL, CouL, and SimL respectively). These four 
enzymes were expressed and purified as described previously43, 69, 103, 110, and used for in 
vitro assays of aminocoumarin acyl ligase activity using 3-amino-4,7-dihydroxy-8-methyl-
coumarin as amino substrate and the six catechols as acyl substrates. The formation of 
the amide bond was analysed by HPLC and the identity of the resulting compounds was 
confirmed by LC-MS. As shown in Figure III.1, the best accepted catechol substrate was 
3,4-dihydroxybenzoic acid (3,4-DHBA), and the most efficient amide synthetase was CloL, 
which reached 42% of the reaction velocity observed with the genuine substrate Ring A 
(Figure III.1B). Caffeic acid was not accepted by CloL, but by SimL and NovL albeit with 
very low efficiency. The other four catechols were not accepted by any of the investigated 
enzymes. We therefore concentrated our efforts on 3,4-DHBA and the aminocoumarin acyl 
ligase of clorobiocin biosynthesis, i.e. CloL. 
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Figure III.1:  
(A) Activity of different aminocoumarin acyl ligases (amide synthetases) with acyl substrates containing 
catechol motifs. Amide bond formation was determined with 3-amino-4,7-dihydroxy-8-methyl-coumarin as 
amino substrate in the presence of ATP and Mg2+, as described in Materials and Methods. (B) HPLC 
chromatogram showing the product formation of the aminocoumarin acid with 3,4-DHBA under the catalysis 
of different aminocoumarin acyl ligases. 
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III.1.2. Inactivation of cloQ in the biosynthetic gene cluster of clorobiocin, and 
heterologous expression of the modified gene cluster  
 
In order to replace Ring A in clorobiocin with 3,4-DHBA, the biosynthesis of Ring A had to 
be abolished to avoid competition between the genuine and the artificial acyl moiety as 
precursor in the antibiotic biosynthesis. The first step in Ring A biosynthesis is the 
prenylation of 4-hydroxyphenylpyruvate catalysed by CloQ93. Therefore, we chose to 
inactivate cloQ in cosmid clo-BG131, which contains the entire biosynthetic gene cluster of 
clorobiocin and elements for stable integration in the Streptomyces chromosome by 
RED/ET-mediated recombination47 to generate cosmid clo-SA2 (see II.2.8.). This cloQ 
deficient gene cluster was integrated into the genome of S. coelicolor M512 at the ΦC31 
attachment site, resulting in S. coelicolor M512(clo-SA2).  
Cultivation of this strain in clorobiocin production medium did not result in production of 
clorobiocin, while similar experiment with S. coelicolor M512 containing the intact gene 
cluster clo-BG1 resulted in the expected production of clorobiocin31, 37. Feeding of Ring A 
restored production of clorobiocin, as confirmed by HPLC, LC-MS analysis and 
comparison with an authentic reference compound. This demonstrated that the inactivation 
of cloQ led to the abolishment of the production of Ring A, but had not affected the 
subsequent steps of clorobiocin biosynthesis (Figure III.2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.2: 
HPLC analysis of the cloQ defective S. coelicolor M512(clo-SA2). (A) 1 mM clorobiocin standard;  
(B) analysis of clorobiocin production in S. coelicolor M512(clo-BG1); (C) abolishment of clorobiocin 
production in the cloQ defective strain S. coelicolor M512(clo-SA2); (D) restored production of clorobiocin 
after complementation of S. coelicolor M512(clo-SA2) by feeding of 1 mg Ring A. 
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III.1.3. Mutasynthetic experiments with 3,4-DHBA and caffeic acid 
 
Feeding of different amounts of 3,4-DHBA to cultures of S. coelicolor M512(clo-SA2) did 
not lead to the formation of a clorobiocin derivative, as shown in HPLC and LC-MS 
analysis. In parallel experiments, we also fed caffeic acid to S. coelicolor M512 expressing 
clo-SA2 and the SimL expression plasmid pSH24, since SimL but not CloL was able to 
accept caffeic acid (Figure III.1A). These experiments were also unsuccessful, but we 
noticed that caffeic acid was clearly detected in the cultures after feeding, while no 
detectable amounts of 3,4-DHBA were present in the cultures already one day after 
feeding. We speculated that 3,4-DHBA may rapidly be oxidised in the medium, or quickly 
metabolised by catabolic pathways similar to those described in Corynebacterium78. We 
therefore considered whether a continuous in vivo biosynthesis of 3,4-DHBA might be 
more efficient than external feeding of this compound, in order to supply 3,4-DHBA for 
aminocoumarin antibiotic formation. 
 
 
III.1.4. Creating an artificial pathway to 3,4-dihydroxybenzoic acid  
 
3,4-DHBA can be formed by the well characterised 4-hydroxybenzoate-3-hydroxylase 
PobA of Corynebacterium cyclohexanicum (Figure III.3)41, 57. This 44 kDa flavoprotein 
monooxygenase is involved in catabolic processes, e.g. lignin degradation. In all Gram-
positive bacteria, it uses NADH to provide the required reduction equivalents. The 
substrate of PobA, 4-hydroxybenzoic acid (4-HBA), is not expected to be present in 
Streptomyces in high concentrations. 4-HBA is an intermediate of ubiquinone biosynthesis. 
In most organisms, it is formed by degradation of tyrosine77. However, Gram-negative 
bacteria such as E. coli synthesise 4-HBA directly from chorismate by elimination of the 
enol-pyruvyl side chain under catalysis of chorismate pyruvate lyase, a 19 kDa protein 
encoded by the gene ubiC (Figure III.3)106. The reaction does not require cofactors. By 
heterologous expression of ubiC in the chloroplasts of plants, which do not contain an 
ortholog of this gene, very large amounts of 4-HBA could be generated without any 
detrimental effect on growth118. Also Streptomyces genomes do not contain an ortholog of 
ubiC. An expression of both ubiC and pobA therefore presented an attractive possibility to 
generate 3,4-DHBA in our Streptomyces strains in vivo.  
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Figure III.3:  
Strategy for the generation of a clorobiocin derivative containing a 3,4-dihydroxybenzoyl moiety. Cosmid clo-
SA2 contains the entire clorobiocin gene cluster with cloQ inactivated. 
 
The GC content of ubiC of E. coli is 53%, much lower than 70%, the approximate average 
content in genes of the GC-rich Streptomyces. Therefore, the sequence of ubiC was 
modified in order to adapt it to the codon preference of Streptomyces. The Gene Designer 
program (DNA 2.0, USA) was used for this purpose, using the codon usage table of 
Streptomyces coelicolor. The same was applied for the gene pobA of Corynebacterium 
cyclohexanicum, although fewer modifications were required for this gene 
(Corynebacterium is also a GC-rich species). The two genes were translationally coupled 
in order to increase translation efficiency and to facilitate co-regulation. The nucleotide 
sequence of the synthetic ubiC/pobA construct is given in Figure III.4. After in vitro 
synthesis (DNA 2.0, USA), this DNA fragment was cloned into the Streptomyces 
expression vector pUWL20128, placing it under control of the strong constitutive ermE* 
promoter. The resulting plasmid, pSA11, was introduced into S. coelicolor M512(clo-SA2) 
by protoplast transformation. Thereby, all genes required for the biosynthesis of the 
desired compound were assembled in the heterologous expression strain (Figure III.3). 
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AAGCTTATGAGCCACCCCGCCCTCACCCAGCTGCGGGCGCTCCGGTACTTCACCGAGATCCCGGCGCTGGAGCCCCAGCT
CCTCGACTGGCTGCTCCTGGAGGACTCGATGACCAAGCGCTTCGAGCAGCAGGGCAAGACCGTCAGCGTCACCATGATCC
GGGAGGGCTTCGTGGAGCAGAACGAGATCCCCGAAGAACTGCCGCTCCTGCCCAAGGAGTCCCGGTACTGGCTCCGGGAG 
ATCCTGCTCTGCGCCGACGGGGAGCCCTGGCTGGCCGGCCGGACCGTCGTGCCGGTGTCCACCCTCAGCGGCCCGGAGCT
GGCGCTCCAGAAGCTGGGCAAGACCCCGCTGGGCCGGTACCTCTTCACCTCGTCCACGCTCACCCGGGACTTCATCGAGA
TCGGCCGCGACGCCGGCCTGTGGGGGCGCCGCAGCCGCCTGCGCCTCAGCGGGAAGCCCCTGCTGCTGACGGAGCTGTTC 
CTGCCGGCGTCCCCGCTGTACTGATGGGGGACCGGACCGTCATCACCACGCAGGTCGCGATCATGGGTGCGGGTCCGGCC
GGGCTCATGCTGTCCCACCTCCTCCACCAGGCCGGTATCGAAAACACGGTGGTGGAGATCCGGTCCCGCGCGGAGATCTC
CGCCACCATCCGGGCCGGCATCCTGGAGGCCGGTTCGGTCGACCTGCTGGTCCAGAGCGGCGTCGACAACGTCCTCCGGA 
ACGGCCACGAACACGAAGGCACCGAGTTCCGCGTCAACGGCGAGGGCCACCGCATCGACTTCAAGGGCCTGGTCGGGCAG
AGCGTCTGGCTGTACCCCCAGAACGACGTCTTCGACGACCTCGCCGCCCGGCGCGAAACGGACGGCGGCGACGTCCGCTA
CTCGTGCAGCAACACCGAGGCCTTCGACCTGCTCGACAAGCCCCGCGTCCACTTCACCGACAGCGAAGGGAACGACTTCG 
AACTCCGCGCCGAGATCCTGGTCGGGGCCGACGGGTCCCGGAGCTACTGCCGGCACCAGATCCCCGAAGCCGCCCGGAAG
ACCTACTTCAACGAGTACCCGTTCGCCTGGTTCGGCATCCTGACCGAGGCGCCGCGCAGCGCGCCCGAGCTCATCTACGC
CAACAGCCCCCACGGCTTCGCCCTGATCAGCCAGCGCACCGACACCGTCCAGCGGATGTACTTCCAGTGCGACCCCACCA 
CCAACCCCGCCGACTGGACCGACGAGCAGATCTGGGAGCAGCTCCGCCTGCGCGTCAACGGTAACGGTTTCGAGCTCAAG
GAGGGCCCCGTGACCGACAAGGTCGTGCTGCCCTTCCGGTCCTTCGTGCAGACCCCGATGCGCCACGGCAACCTCTTCCT
CGCCGGCGACGCCGCGCACACGGTGCCGCCGACCGGGGCGAAGGGCCTCAACCTGGCCTTCTCGGACGTCCGCGTGCTGT 
TCGAATCGCTGGACAGCTACTTCAAGAGCGGCTCCACGGCCCTCATGGACACCTACTCCGAGCGCGCGCTGGACCGGGTG
TGGAAGGCGCAGTACTTCTCGTACTGGATGACCACCCTGCTGCACACCGTGCCGACCGAGACGAACCACGAATTCTTCCG
CGCCCGGCAGCTGGGGGAGCTCCGCTCGCTGCTCGAGTCGGAGCGCGGTCGGGCCTACATCGCCGAGTGCTACACCGGCT 
GGCAGTCCAAGTGAACTAGT 
 
Figure III.4: 
Nucleotide sequence of the synthetic ubiC/pobA DNA fragment. Underlined letters represent the flanking 
HindIII and SpeI restriction sites. The bold letters show the start and stop codons of the synthetic genes ubiC 
and pobA. The genes are translationally coupled, with the stop codon of ubiC overlapping the start codon of 
pobA. 
 
 
III.1.5. Production of novclobiocin 401 by S. coelicolor M512(clo-SA2) harbouring 
plasmid pSA11 
 
S. coelicolor(clo-SA2) harbouring pSA11 was cultivated in three different media: i) the 
complex clorobiocin production medium described for the wild type producer strain 
Streptomyces roseochromogenes var. oscitans DS 12.97672; ii) the complex GYM medium 
described for S. coelicolor A(3)2 fermentation105; iii) the chemically defined medium (CDM) 
developed for novobiocin production in the wild type producer strain Streptomyces 
niveus60. Ethyl acetate extracts from cultures in three media were analyzed by HPLC and 
LC-MS. The formation of a new compound with the expected molecular ion of m/z 643 M-
H- was detected in all media. The compound was not detected in extracts from S. 
coelicolor(clo-SA2) lacking plasmid pSA11. The amount of this compound was moderate 
using the two complex media (4 µg/ml and 7 µg/ml, respectively), but was much higher 
using the chemically defined medium (64 µg/ml). In this case, the new metabolite clearly 
represented a major compound in the extract (Figure III.5A). Preparative isolation of this 
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metabolite from 2 l of culture resulted in 18 mg of pure compound (Figure III.5B). This new 
clorobiocin derivative was termed novclobiocin 401.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.5: 
(A) HPLC chromatogram of a culture extract from the heterologous producer strain Streptomyces coelicolor 
M512(clo-SA2)/pSA11 cultivated in CDM medium. (B) Purified compound isolated from cultures in CDM 
medium. (C) Mass spectrometric fragmentation (MS-MS) of novclobiocin 401 obtained by selected ion 
monitoring chromatograms. LC-ESI-MS mass scans were performed in negative mode for m/z 643. The 
suggested fragmentation scheme for the compound is shown. 
 
 
III.1.6. Structure elucidation of novclobiocin 401  
 
LC-MS analysis in negative mode showed the presence of the molecular ion of m/z 643 
M-H-, corresponding to the expected molecular mass of 644 for novclobiocin 401. MS/MS 
analysis (Figure III.5C) showed a fragmentation pattern corresponding to that identified in 
previous mass spectrometric studies of aminocoumarin antibiotics58. High resolution ESI-
MS in positive mode showed a molecular ion of m/z = 645.14858, which is in agreement 
with the calculated value of m/z = 645.14818 (C30H30N2O12Cl [M+H]+; Δ0.62 ppm). 
Unidimensional (1H NMR, 13C NMR) and multidimensional (1H 1H COSY, 1H HSQC and 1H 
HMBC) NMR spectroscopy confirmed the expected structure (Figure III.6). Chemical shifts 
for the substituted pyrrole, the deoxysugar and the aminocoumarin moiety were in 
accordance to those of clorobiocin32.  
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Figure III.6: 
1H NMR (A) and 1H HSQC (B) for the structure confirmation of novclobiocin 401. 
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The chemical shifts and coupling patterns of the protons in 1H NMR spectra of 
novclobiocin 401 showed the catechol structure of the new acyl moiety. A strong high-field 
13C NMR shift for carbon C-2 (δC = 116.1) and C-4 (δC = 150.8) in novclobiocin 401 
compared to clorobiocin (δC-2 = 130.9, δC-4 = 161.0) indicated a new hydroxyl substitution 
in ortho-position (C-3). Additionally, the NMR spectra of novclobiocin 401 lack all proton 
and carbon NMR signals of the dimethylallyl group of the native clorobiocin. Full 
comparative 1H and 13C NMR spectroscopic data of novclobiocin 401 and clorobiocin are 
given in Table III.1. 
 
 
 
 
 
 
 
 
 
Position  1H-NMR data  
(150.8 MHz, CD3OD),  
δH [ppm], intensity, m, J [Hz] 
 
13C-NMR data  
(125.7 MHz, CD3OD),  
δC [ppm] 
 novclobiocin 401 
 
clorobiocin novclobiocin 401 clorobiocin 
1   125.6 124.2 
2 7.42, 1H, br s 7.76, 1H, d 
(2.5) 
116.1 130.9 
3   146.2 129.9 
4   150.8 161.0 
5 6.80, 1H, d (6.9) 6.84, 1H, d 
(8.4) 
115.8 115.6 
6 7.39, 1H, d (6.9) 7.72, 1H, dd  
(8.4, 2.5) 
121.7 128.5 
7 -- 3.34, 2H, d 
(7.1) 
-- 29.2 
8 -- 5.35, 1H, br t 
(7.1) 
-- 123.2 
9   -- 133.8 
10 -- 1.74, 1H, s -- 17.9 
11 -- 1.75, 3H, s -- 26.0 
7 in 1,  
12 in 2  
  169.6 170.0 
2‘   161.8 162.4 
3‘   102.5 103.7 
4‘   161.7 157.8 
5‘ 7.82, 1H, d (7.1) 7.90, 1H, d 
(9.2) 
124.1 123.9 
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6‘ 7.22, 1H, d (7.1) 7.33, 1H, d 
(9.2) 
111.9 112.5 
7‘   150.0 161.8 
8‘   110.2 110.7 
9‘   156.1 156.5 
10‘   110.5 113.3 
1‘‘ 5.72, 1H, d (2.0) 5.73, 1H, d 
(1.8) 
100.2 100.4 
2‘‘ 4.38, 1H, br m 4.34, 1H, dd 
(2.7) 
71.0 71.0 
3‘‘ 5.70, 1H, dd (11.1, 
2.0) 
5.71, 1H, dd 
(10.3, 2.9) 
71.6 71.6 
4‘‘ 3.72, 1H, d (11.1) 3.72, 1H, d 
(10.3) 
82.7 82.7 
5‘‘   80.4 80.5 
6‘‘ 1.17, 3H, s 1.18, 3H, s 22.9 22.9 
7‘‘ 1.35, 3H, s 1.35. 3H, s 29.3 29.3 
8‘‘ 3.52, 3H, s 3.52, 3H, s 62.0 62.1 
2‘‘‘   121.5 121.8 
3‘‘‘ 6.89, 1H, d (3.4) 6.90, 1H, d 
(3.6) 
118.2 118.33 
4‘‘‘ 5.93, 1H, d (3.4) 5.94, 1H, br d 
(3.6) 
109.7 109.8 
5‘‘‘   136.1 136.3 
6‘‘‘ 2.29, 3H, s 2.29, 3H, s 13.0 12.9 
7‘‘‘   161.8 161.8 
 
Table III.1:  
Full comparative 1H and 13C NMR spectroscopic data of novclobiocin 401 and clorobiocin. Chemical shifts 
are expressed in δ values using the solvent as internal standard (CD3OD). Assignments for novclobiocin 401 
were made using 2D NMR data; assignments of clorobiocin were taken from literature32. 
 
 
III.1.7. Inhibitory activities against E. coli and S. aureus DNA gyrase and 
topoisomerase IV. 
 
The new compound was investigated in vitro for its inhibitory effects on E. coli and S. 
aureus DNA gyrase and topoisomerase IV in comparison with the natural antibiotics 
clorobiocin and novobiocin. Two different assays were used: a DNA gyrase supercoiling 
assay and a topoisomerase IV decatenation assay. The 50% inhibitory concentration (IC50) 
of the catechol compound was determined as 0.006 µM for S. aureus DNA gyrase and 
0.03 µM for E. coli DNA gyrase (Figure III.7A). These inhibitory concentrations are 
identical to those observed with clorobiocin and lower than those observed with the 
clinically used novobiocin (inhibitory concentration: 0.01 µM and 0.08 µM respectively) 
against the two gyrases. This clearly proves that the replacement of the genuine Ring A 
moiety with a 3,4-DHBA moiety had not affected the potency of the compound as gyrase 
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inhibitor, what is in agreement with the structural information indicating that Ring A is not 
involved in the interaction with DNA gyrase (see Introduction).  
DNA gyrase inhibitors of the fluoroquinolone class also inhibit topoisomerase IV which is 
very similar to gyrase74. Thus, we examined whether novclobiocin 401 also inhibits the 
decatenation activity of E. coli and S. aureus topoisomerase IV. However, just as 
novobiocin and clorobiocin, the new compound inhibited topoisomerase IV from S. aureus 
and E. coli only at much higher concentrations than those required for gyrase inhibition 
(IC50 values: 35 µM for S. aureus gyrase and >50 µM for E. coli gyrase) (Figure III.7B). 
Therefore, novclobiocin 401 is expected to act primarily as gyrase inhibitor in both S. 
aureus and E. coli.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.7: 
Supercoiling (A) and decatenation (B) assays with E. coli and S. aureus DNA gyrase and topoisomerase IV. 
The first lane labelled with C contains control assays without enzyme. The lane labelled 0 contains assays 
with addition of 3 l solvent (5% aqueous DMSO). The following lanes contain assays to which the indicated 
amount of antibiotic, dissolved in 5% DMSO, has been added. In the supercoiling assays, the lower band 
shows supercoiled pBR322 DNA, formed under catalysis of DNA gyrase. In the decatenation assays, the 
lower band shows decatenated kinetoplast DNA, formed under catalysis of topoisomerase IV. 
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III.1.8. Construction of E. coli mutants for investigation of antibiotic import by 
catechol siderophore transporters  
 
As reported above, E. coli gyrase is equally sensitive to clorobiocin and novclobiocin 401, 
but novclobiocin 401 has been designed for a more efficient transport inside the cell than 
clorobiocin and therefore exert higher antibacterial activity in vivo. In order to study the 
differences in influx without interference by differences in efflux, we inactivated the gene 
tolC, which encodes an essential part of the AcrABTolC drug efflux pumps of E. coli 
(Figure III.8A)15. 
E. coli possesses three outer membrane transporters for active import of catechol 
siderophores: Fiu, Cir, and FepA18. All three transporters receive the energy for active 
transport from the periplasmic-located protein TonB. Therefore, the role of the catechol 
siderophore transporters Fiu, Cir, and FepA in the uptake of novclobiocin 401 can be 
investigated by comparing the sensitivity to clorobiocin and novclobiocin 401 of mutants 
with and without active TonB (Figure III.8A). Expression of these proteins is up-regulated 
under conditions of iron starvation. Bacterial growth during an infection in the human body 
represents a condition of extreme iron starvation24. For functional studies of catechol 
siderophore transport in E. coli, conditions of iron starvation are usually created by i) 
mutation of entC, which abolishes the biosynthesis of the important siderophore 
enterobactin26; ii) addition of the iron chelator 2,2'-bipyridyl to the culture medium2, 79. In 
order to investigate the importance of the outer membrane as a resistant mechanism of 
Gram-negative bacteria, we considered to test the three aminocoumarins also with E. coli 
strains defective in the outer membrane. A mutation in the gene rfaP, encoding for a 
lipopolysaccaride kinase that is essential for the outer membrane stability127, causes a 
hyperpermeable membrane for lipophilic antibiotics by mutational alteration of its 
lipopolysaccaride components (Figure III.8A).   
Single in-frame knockout mutants of entC, tolC, tonB and rfaP in E. coli K-12 were 
available from the Keio collection8. Using these strains, we generated several E. coli 
double and triple mutants by RED/ET-mediated recombination, shown in Figure III.8B, to 
compare their sensitivity to clorobiocin and novclobiocin 401 in culture media containing 
2,2'-bipyridyl. The correct genotype of the mutants was verified by PCR analysis (Colony 
PCR) of the genomic DNA of the mutant.  
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Figure III.8: 
(A) Overview of the catechol-mediated drug influx and AcrAB-TolC-mediated drug efflux in E. coli. Cir and 
Fiu are TonB dependent receptors in the outer membrane (OM). In an energy dependent way they catalyse 
the uptake of siderophore-drug-conjugates. The ABC transporter (Fep system) transports the siderophore-
drug-conjugate across the inner membrane (IM) into the cytoplasm. The lipopolysaccaride kinase RfaP is 
essential for the outer membrane stability; inactivation of rfaP results in a mutant which is hypersensitive to 
aminocoumarins114, 127. (B) Overview on the constructed multiple mutations of E. coli strains by RED/ET-
mediated recombination based on strains from the Keio-collection8. 
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III.1.9. Determination of the antibacterial activity of novclobiocin 401 in agar 
diffusion  tests 
 
The antibacterial activity of novclobiocin 401, in comparison to clorobiocin and novobiocin, 
was first tested in agar diffusion assays with the E. coli ΔtolC and E. coli ΔtolC/ΔentC 
mutants compared with the E. coli ΔtonB/ΔtolC and E. coli ΔtonB/ΔtolC/ΔentC mutants. To 
improve visualisation of the inhibition zones, living cells on the agar plates were stained 
with 2,3,5-triphenyltetrazolium chloride. The results are shown in Figure III.9AB. Against 
the mutants with intact TonB, and therefore functional siderophore uptake, novclobiocin 
401 shows approximately 2-fold higher activity than clorobiocin, and 4-fold higher activity 
than novobiocin. In contrast, against the E. coli mutants with deleted tonB, novclobiocin 
401 is approximately 10-fold less active than clorobiocin. As expected the antibacterial 
activity is more pronounced with an additional entC mutation, because the production of 
the own siderophore enterobactin is abolished and therefore bacteria grow under iron 
starvation and are more sensitive to drugs. 
These results show that TonB-dependent transport plays an important role in the 
antibacterial activity of novclobiocin 401 but not in the activity of clorobiocin and 
novobiocin, what indicates that i) aminocoumarin antibiotics are efficiently introduced 
inside E. coli and the previously observed resistance114 is due mainly to the multi-drug 
efflux pump of which TolC is an important component; and ii) the exchange of the natural 
Ring A of clorobiocin with 3,4-DHBA diminishes the uptake of the antibiotic through the 
usual path for clorobiocin and novobiocin. This is in accordance with former literature that 
Ring A plays a crucial role for the uptake into bacterial cells1, 98. 
Agar diffusion assays with an E. coli ΔrfaP/ΔentC mutant support the hypothesis that the 
outer membrane is not the main resistance mechanism of Gram-negative bacteria against 
aminocoumarins. The antibacterial activity of aminocoumarins is much more increased in 
bacteria with an efflux pump defect (E. coli ΔtolC/ΔentC mutant) (Figure III.9B) than with 
an outer membrane defect (E. coli ΔrfaP/ΔentC mutant) compared with an E. coli ΔentC 
mutant which is not affected at all by aminocoumarins (Figure III.9C). However, it remains 
unclear why the ΔrfaP mutant (supposed to have a hyperpermeable membrane) shows 
higher resistance to novclobiocin 401 than to clorobiocin or novobiocin (indistinct inhibition 
zone of 8 mm with 10 µg compound; Figure III.9C). A possible explanation is given in 
section III.1.10. 
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Figure III.9: 
Disk diffusion assay for the determination of the antibacterial activity of clorobiocin, novobiocin, and 
novclobiocin 401 against E. coli mutants with and without active TonB (A B) and with and without active 
RfaP (C). At the same time the importance of TolC for the antibacterial activity of aminocoumnarins is shown. 
To improve visualization of the inhibition zones, living cells were stained with 2,3,5-triphenyltetrazolium 
chloride. 
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Table III.2 shows the mean values, from at least three separate experiments, of the 
inhibition zones obtained with different amounts of novobiocin, clorobiocin and 
novclobiocin 401 (0.5 µg, 1.5 µg, 5 µg, 10 µg) against the described E. coli mutants in agar 
diffusion tests.  
 
mean of inhibition zone (mm) caused by test compounds 
0.5 µg 1.5 µg 5 µg 10 µg 
E. coli  
strain 
nov clo 401 nov clo 401 nov clo 401 nov clo 401 
ΔtolC 9 9.3 14 11 13.8 16.3 15.5 17.5 19.3 18.3 19.2 21 
ΔtolC/ΔentC 10.5 10.6 15.3 12.5 15.2 21.3 18.3 18.4 25.6 21 19.8 26 
ΔtonB/ΔtolC 10.3 11.3 8 14 15.3 12.6 18.6 19.6 17.3 22.6 21.6 19.6
ΔtonB/ΔtolC/ΔentC 11.8 13 9.5 16 17.5 10 20 21.5 16 22.3 23 19.3
ΔrfaP/ΔentC 0 0 0 13.3 11.5 0 16.6 13 0 19.6 15.6 8 
ΔentC 0 0 0 0 0 0 0 0 0 0 0 0 
K12 (wild type) 0 0 0 0 0 0 0 0 0 0 0 0 
 
Table III.2: 
Inhibition zones obtained with novobiocin (nov), clorobiocin (clo) and novclobiocin 401 (401) against 
genetically defined E. coli mutants in agar diffusion tests, performed in Mueller-Hinton-Agar; tested 
compounds were dissolved in MeOH; inhibition zones are averages from at least three separate 
experiments. 
 
After the evaluation of the inhibition zones the statistical t-test was performed to test 
whether the antibacterial activity of novclobiocin 401 was significantly better than that of 
clorobiocin or novobiocin. It is generally accepted that if a specific parameter (p value) in 
the t-test is lower than 0.05 then the antibacterial activities are different with statistical 
significance, i.e. with 95% probability. 
Figure III.10 shows that the antibiotic activities of novobiocin and clorobiocin against the 
E. coli ΔtolC/ΔentC mutant are not significantly different (p value >0.05). In contrast, 
novclobiocin 401 showed a significantly better antibacterial activity than novobiocin and 
clorobiocin against this mutant (p value <0.05). On the other hand, novclobiocin 401 
showed a significantly lower activity against the E. coli mutants without active TonB than 
clorobiocin or novobiocin, what demonstrates that Ton B is involved in the uptake of 
novclobiocin 401 into the Gram-negative cell. 
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Figure III.10: 
Statistical t-test to determine the significant differences in the antibacterial activity of novclobiocin 401 in 
comparison with novobiocin and clorobiocin. Both graphs represent the mean of inhibition zones caused by 
the tested compounds (10 µg) against E. coli mutants with and without active TonB. Error bars indicate the 
calculated standard deviations. 
 
 
 
III.1.10. Growth promotion with enterobactin 
 
The observation that novclobiocin 401 was not able to enter the hyperpermeable 
membrane mutant E. coli ΔrfaP/ΔentC, unlike clorobiocin or novobiocin, was unexpected. 
To investigate this further, we performed growth promotion assays with the E. coli 
siderophore enterobactin. We hypothesised that due to the alteration of the 
lipopolysaccarids (caused by ΔrfaP mutation) the siderophore transporters, located in the 
outer membrane, might have been also affected. This could be a reason why novclobiocin 
401 can not be transported inside the cell and shows less antibacterial activity. Therefore, 
we compared the E. coli ΔentC and E. coli ΔrfaP/ΔentC mutants, both unable to form their 
own siderophore enterobactin, under iron-restricted conditions. After addition of 
enterobactin to the E. coli ΔentC mutant, growth could be observed. In contrast, the E. coli 
ΔrfaP/ΔentC mutant showed less ability to grow on iron diminished medium what points to 
a lack of iron transport into the cell (Figure III.11). This experiment gives a possible 
explanation of the limited influx of novclobiocin 401 through the hyperpermeable 
membrane, which like enterobactin is transported by siderophore transporters.  
0
2
6
10
14
18
22
26
30
in
hi
bi
tio
n
zo
ne
(m
m
)
novobiocin novclobiocin 
401
clorobiocin
E. coli ΔtolC/ΔentC
0
2
6
10
14
18
22
26
30
in
hi
bi
tio
n
zo
ne
(m
m
)
E. coli ΔtonB/ΔtolC/ΔentC
novobiocin novclobiocin 
401
clorobiocin
in
hi
bi
tio
n
zo
ne
(m
m
)
0.008novclobiocin 401clorobiocin
0.022novclobiocin 401novobiocin
0.502clorobiocinnovobiocin
p valueComparison of:
0.032novclobiocin 401clorobiocin
0.056novclobiocin 401novobiocin
0.770clorobiocinnovobiocin
p valueComparison of:
RESULTS 
 
66 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.11:  
Role of RfaP in enterobactin-mediated growth promotion. Both strains were grown in iron-restricted medium. 
(a) control (methanol); (b) 0.02 µg enterobactin; (c) 0.01 µg enterobactin. Dark halos indicate bacterial 
growth. 
 
 
III.1.11. Determination of the minimum inhibitory concentration (MIC) of 
novclobiocin 401 
 
We also determined the minimum inhibitory concentration (MIC) in liquid culture, following 
the procedure described by Wiegand and co-workers123, but including 50 µM of the iron 
chelating agent 2,2'-bipyridyl to the culture media. Under these conditions, novobiocin and 
clorobiocin MIC against E. coli ΔtolC/ΔentC double mutant was 23 and 12 µg/ml 
respectively. The MIC of novclobiocin 401 was 6 µg/ml, showing again that novclobiocin 
401 has higher antibacterial activity than its parent compound clorobiocin. Against the 
ΔtonB/ΔtolC/ΔentC triple mutant, novobiocin and clorobiocin gave the same MIC values as 
observed against the ΔtolC/ΔentC double mutant (23 and 12 µg/ml, respectively). 
However, novclobiocin 401 showed much less activity against the tonB-deficient triple 
mutant (MIC: 47 µg/ml) than against the double mutant with active tonB (MIC: 6 µg/ml). 
This shows again that TonB-dependent transport is important for the antibacterial activity 
of novclobiocin 401, but not of novclobiocin and clorobiocin. 
Against the wild-type strain E. coli K-12, the MICs of novobiocin, clorobiocin and 
novclobiocin 401 resulted as 375, 47 and 95 µg/ml respectively. Similar values were 
obtained against the ΔentC mutant. Therefore, against these strains novclobiocin 401 was 
less active than its parent compound clorobiocin. The poor activity of aminocoumarins 
against wild-type strains of E. coli is in accordance with previous observations5, 44. 
E. coli ΔentC
cb
a
1 cm
cb
a
E. coli ΔentC/ΔrfaP
RESULTS 
 
67
III.2. Generation of a clorobiocin derivative containing the catechol 
moiety 2,3-dihydroxybenzoic acid 
 
III.2.1. Activation of 2,3-dihydroxybenzoic acid by the AMP ligase DhbE from 
Bacillus subtilis 
 
After the generation of a clorobiocin derivative with the siderophore-like structure 3,4-
dihydroxybenzoic acid (novclobiocin 401), the production of a second clorobiocin 
derivative with 2,3-dihydroxybenzoic acid (2,3-DHBA) was of great interest as the 
siderophores enterobactin from E. coli and bacillibactin from B. subtilis contain this 
catechol motif.  
In amide synthetase assays (see III.1.1.) we found that none of the four available acyl 
ligases (NovL, CloL, CouL, SimL) accepted 2,3-DHBA as substrate. Normally, the acyl 
ligases catalyze two steps, the adenylation of the acyl moiety and the following attachment 
to the aminocoumarin moiety.  
The required genes for the biosynthesis of 2,3-DHBA, precursors of the siderophore 
bacillibactin75, are organized in a single operon in B. subtilis. Conspicuous is that a special 
enzyme, an AMP ligase, is present to catalyze the activation of 2,3-DHBA to 2,3-DHB 
adenylate (Figure III.12).  
 
 
 
 
 
 
 
 
 
 
 
Figure III.12: 
Enzymes of bacillibactin biosynthesis. 
 
We concluded that 2,3-DHBA needs a special activation, which can not be catalysed by 
any of the acyl ligases alone. We design the in vitro adenylation of 2,3-DHBA to study its 
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acceptance by the for amide synthetases. Plasmid pJJM301, that contains dhbE from B. 
subtilis, was kindly provided by the laboratory of Prof. M. Marahiel (Marburg, Germany). 
Soluble, N-terminally his-tagged protein DhbE was obtained after expression of plasmid 
pJJM301 in E. coli BL21/pREP4 cells. Ni2+-affinity chromatography resulted in 
approximately 21 mg of purified DhbE from one litre LB-culture. The apparent molecular 
mass in SDS-PAGE analysis was consistent with the predicted molecular weight of the 
polypeptide encoded by dhbE (59.9 kDa) (Figure III.13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.13: 
SDS PAGE of the expression and purification of the AMP ligase DhbE from B. subtilis 
 
We then performed in vitro amide synthetase assays as described in section II.3.6 but 
containing equal amounts of purified DhbE and of one of the acyl ligases per assay. 2,3-
DHBA was efficiently adenylated by purified DhbE, and the activated catechol was readily 
accepted as substrate by the four available amide synthetases and connected to the 
coumarin moiety (Figure III.14).  
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Figure III.14: 
(A) HPLC chromatogram of an amide synthetase assay containing CloL and DhbE in equal amounts; the 
arrow indicates the product formation of the aminocoumarin acid with 2,3-DHBA moiety. (B) LC-MS 
chromatogram showing the MS-MS main ion scan for m/z 344 in positive mode. (C) Mass spectrometric 
fragmentation of the novclobiocin acid with 2,3-DHBA moiety obtained by selected ion monitoring 
chromatograms. The suggested scheme for the compound is shown. 
 
Therefore, the reason for the failed reaction described in section III.1.1 was the required 
pre-activation by DhbE (Figure III.15).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.15: 
Suggested activation of 2,3-DHBA by the AMP ligase DhbE by an adenylation reaction and the following 
transfer to the aminocoumarin moiety catalyzed by amide synthetases under catalysis of ATP. 
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III.2.2. Detection of the clorobiocin derivative with 2,3-dihydroxybenzoic acid 
 
S. coelicolor genome contains a gene cluster for a hypothesised zinc-chelating compound, 
called coelibactin11, 51. The first gene in this hypotetical cluster, sco7681, encodes a 
putative AMP-binding ligase with 52% amino acids homology to DhbE from B. subtilis. We 
considered that this DhbE homolog could activate 2,3-DHBA in a similar way than DhbE of 
the catechol siderophore griseobactin found in S. griseus89. 
The first attempts to obtain the new clorobiocin derivative by feeding of 2,3-DHBA to S. 
coelicolor M512(clo-SA2) remained unsuccessful, although 2,3-DHBA, in contrast to 3,4-
DHBA, could be detected over several days in the culture and therefore the problem of 
rapid degradation of the catechol by Streptomcyes was not the problem. This could be due 
to lack of expression of sco7681 under our working conditions. 
We then tried to synthesise 2,3-DHBA in S. coelicolor M512 by introducing the plasmid 
pSP1261110 containing the necessary genes (dhbA, dhbC, dhbE, dhbB; Figure III.12) from 
griseobactin gene cluster of Streptomcyes griseus89. This strategy was also unsuccessful, 
probably because of inefficient expression of the genes from that construct. 
In a further experiment we integrated the cloQ deficient clorobiocin biosynthetic gene 
cluster (clo-SA2) as well as the plasmid pSP1261110 (containing genes for griseobactin 
biosynthesis) into the genome of S. coelicolor M1154 at the ΦC31 attachment site, 
resulting in S. coelicolor M1154(clo-SA2)/pSP1261110. We cultivated this strain in 
chemically defined medium (CDM) and additionally fed 2,3-DHBA to the culture. Ethyl 
acetate extracts from the culture were analyzed by HPLC and LC-MS after 5 d. LC-MS 
analysis in negative mode showed the presence of the molecular ion of m/z 643 M-H-, 
corresponding to the expected molecular mass of 644 for the new clorobiocin derivative 
with 2,3-DHBA. MS/MS analysis (Figure III.16) showed the expected fragmentation 
pattern of the new compound. We think that the activation of the externally added 2,3-
DHBA was actually performed by the AMP-ligase encoded by sco7681 and not by the 
DhbE encoded in pSP1261110, since the formation of this compound was only detected in 
the culture to which 2,3-DHBA was added and therefore the genes in pSP1261110 seem 
not to be expressed. S. coelicolor M1154 is a new host strain especially developed for the 
increased heterologous expression of secondary metabolite gene clusters45 what could 
explain the expression of sco7681 in contrast to M512. 
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Despite we have certainly obtained the desired compound, it is still necessary to optimize 
the conditions for an enhanced production of the new clorobiocin derivative with 2,3-DHBA, 
in order to obtain enough amounts for structure confirmation by NMR and bioactivity tests. 
 
 
 
 
 
 
 
 
 
 
 
Figure III.16: 
LC-ESI-MS mass scans were performed in negative mode for m/z 643. Extracted ion chromatogram for the 
main ion m/z 643 [M-H]- of the culture extract S. coelicolor M1154(clo-SA2)/pSP1261110 without feeding of 
2,3-DHBA (A) and with feeding of 2,3-DHBA (B). (C) Mass spectrometric fragmentation of the new 
clorobiocin derivative with 2,3-DHBA obtained by selected ion monitoring chromatograms. The suggested 
fragmentation scheme for the compound is shown. 
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III.3. Inhibition of DNA gyrase and topoisomerase IV of 
Staphylococcus aureus and Escherichia coli by aminocoumarin 
antibiotics 
 
III.3.1. Expression of the subunits of Staphylococcus aureus topoisomerase IV as 
his-tagged proteins  
 
S. aureus DNA gyrase, as well as E. coli topoisomerase IV and DNA gyrase, are 
commercially available, but it was necessary to generate S. aureus topoisomerase IV for 
our study. Expression of the structural genes for ParC and ParE as C-terminally his-tagged 
proteins, using vector pET22b (Novagen) were unsuccessful. However, soluble, N-
terminally his-tagged ParC and ParE proteins were obtained from constructs containing 
parC and parE from S. aureus RN4220 in the pQE70 vector (QIAGEN) which were 
expressed in E. coli BL21/pREP4 cells. Ni2+-affinity chromatography resulted in 
approximately 7 mg of purified ParC and 5 mg purified ParE per litre of culture. The 
apparent molecular mass in SDS-PAGE analysis was consistent with the predicted 
molecular weight of the polypeptides encoded by parC (96.2 kDa) and parE (77.8 kDa) 
respectively. Mixing of equimolar amounts of the two subunits resulted in active 
topoisomerase IV (see below). 
 
 
III.3.2. Removal of potassium glutamate from the assays for DNA gyrase activity 
 
We established assay conditions for the measurement of the inhibition of E. coli and S. 
aureus DNA gyrase and topoisomerase IV by aminocoumarin antibiotics. As described by 
Morgan-Linnell and co-workers80 and Pan & Fisher88 for investigation of the inhibitory 
activity of agents against topoisomerase IV the decatenation assay is the most 
appropriate, while the most relevant assay for agents like aminocoumarins, acting on DNA 
gyrase, is inhibition of supercoiling. The activity of S. aureus DNA gyrase is dependent on 
high concentrations of potassium glutamate (K-Glu)16, 52. However, we found that K-Glu 
concentrations over 400 mM impaired the resolution in the gel electrophoresis analysis of 
the supercoiling assays (Figure III.17, lane b). We tested different methods for desalting 
the samples before loading them in agarose gels. Addition of 700 mM 18-Crown-6 (Fluka) 
after the reaction, intended to complex the potassium cations, led to an undesirable 
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reduction of the intensity of the bands on the agarose gel (Figure III.17, lane c). 
Purification of the assay products with the QIAprep Spin Miniprep Kit for plasmid DNA 
purification (QIAGEN) provided better results (Figure III.17, lane d). The best resolution 
and visualization of the different topoisomers of relaxed DNA was achieved by dialysis 
against a 10 mM Tris-HCl buffer (pH 8.0) using membrane filters (0.025 µm pore diameter) 
(Figure III.17, lane e), and therefore this method was used for all further DNA gyrase 
assays. No dialysis was required for topoisomerase IV activity tests. Kinetoplast DNA was 
used as substrate in these assays, and the resolution in agarose gel electrophoresis was 
satisfactory without removal of K-Glu (Figure III.18). Furthermore, S. aureus 
topoisomerase IV required a lower concentration of K-Glu for activity than DNA gyrase 
(see below). 
 
 
 
 
 
 
 
Figure III.17: 
Electrophoretic analysis of S. aureus DNA gyrase supercoiling assays using different methods for potassium 
glutamate removal. Lane a, assay without K-Glu (the enzyme is inactive under these conditions); lane b to e, 
assays with 700 mM K-Glu; lane b, without removal of K-Glu; lane c, addition of 700 mM 6-Crown-18; lane d, 
desalting with QIAspin Miniprep Kit for plasmid DNA purification (QIAGEN); lane e, dialysis against 10 mM 
Tris-HCl buffer (pH 8.0) with 0.025 µM membrane filters MFTM VSWP (Millipore). 
 
 
III.3.3. Effect of potassium glutamate on the activity of DNA gyrase and 
topoisomerase IV of E. coli and S. aureus 
 
Previous investigations had shown that K-Glu has an important influence on the activities 
of bacterial type II topoisomerases. The optimal K-Glu concentration is different for S. 
aureus and for E. coli enzymes, and different for DNA gyrase and topoisomerase IV. Even 
for the same enzyme of a given origin, the optimal K-Glu concentration varies for different 
assay types, e. g. for the supercoiling and the DNA cleavage assay in case of S. aureus 
DNA gyrase, or for the decatenation and the relaxation assay in case of topoisomerase 
IV16,52, 99. We investigated the influence of K-Glu and Na-Glu in concentrations from 0 mM 
nicked DNA
supercoiled DNA
a             b             c             d              e
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to 1000 mM on the four enzymes relevant to our study, i.e. DNA gyrase and 
topoisomerase IV from both S. aureus and E. coli, using the supercoiling assay for DNA 
gyrase and the decatenation assay for topoisomerase IV (Figure III.18). 
S. aureus DNA gyrase and topoisomerase IV were both inactive in the absence of K-Glu. 
DNA gyrase activity was detectable from 300 - 1000 mM K-Glu, with an optimal 
concentration around 900 mM. Topoisomerase IV activity was detectable between 100 - 
500 mM K-Glu, with an optimal activity between 200 - 400 mM. These data are in 
agreement with the results of the four previous studies on the influence of K-Glu on S. 
aureus topoisomerases16, 52, 99, 112. 
E. coli DNA gyrase is active in the absence of K-Glu, and this may be the reason that only 
few data are available on the influence of K-Glu on type II topoisomerases of E. coli52. Our 
investigations confirmed that E. coli DNA gyrase does not require K-Glu for activity, but 
also showed that inclusion of 200 - 500 mM K-Glu moderately stimulates the activity of this 
enzyme. Using the established amount of enzyme in our standard decatenation assay, 
activity of E. coli topoisomerase IV was not detected in the absence of K-Glu, but clearly in 
the presence of 100 - 500 mM of this salt; the optimal concentration range was 200 – 400 
mM (Figure III.18). Therefore, also E. coli topoisomerase IV is clearly stimulated by K-Glu.  
Blanche and co-workers16 reported that for stimulation of S. aureus DNA gyrase in the 
supercoiling assay, K-Glu could be replaced by its enantiomer, e.g. the potassium salt of 
D-Glu, but not by Na-Glu or KCl. Our investigations confirmed that S. aureus DNA gyrase 
is inactive in the presence of Na-Glu, irrespective of the concentration (Figure III.18). In 
clear contrast, S. aureus topoisomerase IV is stimulated by Na-Glu (200 – 400 mM), 
although less than by K-Glu. Also E. coli topoisomerase IV is weakly stimulated by 200 
mM Na-Glu. Notably, E. coli DNA gyrase is completely inhibited by Na-Glu in 
concentrations of 200 mM or higher (Figure III.18).  
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Figure III.18:  
Effect of K-Glu and Na-Glu on S. aureus and E. coli DNA gyrase in supercoiling assays and on 
topoisomerase IV in decatenation assays. The supercoiling reaction mixtures contained relaxed pBR322 
DNA, DNA gyrase and the indicated concentrations of K-Glu and Na-Glu.  The decatenation reaction 
mixtures contained kDNA, topoisomerase IV and the indicated concentrations of K-Glu and Na-Glu. The first 
lane, labelled with C, contains a control assay without enzyme. In the DNA gyrase assays, the lower band 
shows supercoiled DNA. In the topoisomerase IV assays, the lower band shows decatenated DNA. 
 
It has been shown that a monovalent cation is required for the ATPase activity of this 
family of enzymes and that it seems to exist some specificity for the cation56. To test 
whether potassium is responsible for the catalytic activity of S. aureus DNA gyrase we 
performed similar series of supercoiling assays with 0 mM to 1500 mM KCl or NaCl. S. 
aureus DNA gyrase was inactive regardless the concentration of KCl or NaCl, while the E. 
coli enzyme lost activity from 100 mM onwards of either KCl or NaCl (Figure III.19). Since 
E. coli DNA gyrase does not require nor is affected by K-Glu, the lack of activity observed 
when adding Na-Glu could indicate that the enzyme prefers potassium, and sodium is 
competing for the binding to the enzyme. To test this hypothesis we performed 
supercoiling assays in the presence of 100 mM Na-Glu and increasing concentrations of 
K-Glu up to 400 mM, but K-Glu did not restore enzyme activity (data not shown). 
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Figure III.19: 
Effect of KCl and NaCl on E. coli DNA gyrase in supercoiling assays. The first lane, labelled with C, contains 
a control assay without enzyme. In the DNA gyrase assays, the lower band shows supercoiled DNA. 
 
 
III.3.4. Potassium glutamate modulates the sensitivity of E. coli DNA gyrase to 
aminocoumarin antibiotics 
 
Previous studies have shown that the sensitivity of DNA gyrase to quinolones is modulated 
by K-Glu52, 112. We now tested the influence on K-Glu on the sensitivity of E. coli DNA 
gyrase to aminocoumarin antibiotics. E. coli DNA gyrase was approximately 10-fold more 
sensitive to novobiocin, clorobiocin, and novclobiocin 101 (Figure III.20) in the presence of 
700 mM K-Glu than in its absence (Figure III.21). Unexpectedly, the effect of K-Glu was 
much more pronounced in case of novclobiocin 103, which is an analogue of novobiocin 
lacking the acyl substituent, which is attached in the naturally occurring antibiotic (Figure 
III.20) to the 3-OH group of the deoxysugar moiety. E. coli DNA gyrase was only weakly 
inhibited by this compound in the absence of K-Glu, but sensitivity increased by a factor of 
150 in the presence of K-Glu. X-ray crystallographic studies have shown that the 
carbamoyl group of novobiocin occupies a distinct binding pocket of the DNA gyrase 
protein, providing an important interaction with the target74. Apparently, the relative 
importance of this particular interaction in the overall binding of the antibiotic is reduced in 
the presence of K-Glu.  
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Figure III.20: 
Structure of the novclobiocins used in this study. 
 
The concentration of K-Glu is therefore an important consideration when the inhibitory 
effects of aminocoumarins on DNA gyrase from E. coli and S. aureus are compared. Since 
DNA gyrase from S. aureus does not require K-Glu, we decided to subsequently use 700 
mM K-Glu in assays of DNA gyrases from both organisms that is the concentration 
recommended by Blanche and co-workers16 for assays of S. aureus DNA gyrase and still 
provides 100% of activity of E. coli DNA gyrase.  
The other three enzymes in our study, i.e. DNA gyrase from S. aureus and topoisomerase 
IV from both S. aureus and E. coli, did not show detectable activity in the absence of K-Glu 
under our assay conditions, and therefore the influence of K-Glu on their sensitivities to 
aminocoumarins could not be tested in a similar experiment as described above for E. coli 
DNA gyrase. We decided to use 100 mM K-Glu in subsequent assays for topoisomerase 
IV from both organisms, which is the concentration used in several previous studies35, 90 
and which is recommended by the commercial suppliers of topoisomerase IV, i.e. Inspiralis 
(Norwich, UK) and Topogen (Columbus, Ohio, USA). However, our own data suggest that 
the enzyme activity is slightly higher at 200 – 400 mM K-Glu (Figure III.18). 
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Figure III.21: 
Influence of K-Glu on the sensitivity of E. coli DNA gyrase towards aminocoumarin antibiotics. The 
supercoiling reaction mixtures contained relaxed pBR322 DNA, DNA gyrase and the indicated 
concentrations of the antibiotic. The first lane, labelled with C, contains control assays without enzyme. The 
lanes labelled 0 or 0* contain assays with no addition or with addition of 3 µl solvent (5% aqueous DMSO), 
respectively. The following lanes contain assays to which the indicated amount of antibiotic, dissolved in 5% 
DMSO, has been added. (A) Investigation of novobiocin, clorobiocin and novclobiocin 101. (B) Investigation 
of novclobiocin 103.  
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III.3.5. Inhibition of DNA gyrase and topoisomerase IV from E. coli and S. aureus 
by different aminocoumarin antibiotics 
 
Using the assay conditions established in the preceding experiments, we investigated the 
inhibitory effect of different aminocoumarin antibiotics on DNA gyrase and topoisomerase 
IV from E. coli and S. aureus. We tested the three “classical” aminocoumarin antibiotics 
novobiocin, clorobiocin, and coumermycin A1, as well as the structurally different 
simocyclinone D8 (Figure III.20). We also included several novobiocin and clorobiocin 
derivatives (termed “novclobiocins”), which we had obtained in previous mutasynthesis 
and metabolic engineering experiments4, 32, 35, 126. Novobiocin, clorobiocin, and 
coumermycin A1 were on average 6-fold more active against S. aureus DNA gyrase than 
against E. coli DNA gyrase (Table III.3). The inhibitory concentrations were in the range of 
6-10 nM, i.e. three orders of magnitude lower than reported for fluoroquinolones like 
ciprofloxacin, ofloxacin or sparfloxacin88, 113, 115. This confirms the potency of 
aminocoumarins as DNA gyrase inhibitors in Gram-positive pathogens. However, the 
activity of the aminocoumarins against S. aureus topoisomerase IV was weaker (Table 
III.3). These biochemical data suggest that gyrase is the primary target of the tested 
aminocoumarins in S. aureus. This is supported by the observation by Fujimoto-Nakamura 
and coworkers42, who showed that cultivation of S. aureus in the presence of novobiocin 
resulted first in the selection of mutants with altered DNA gyrase; use of higher 
concentrations of novobiocin additionally resulted in mutations of topoisomerase IV as a 
second step in the emergence of resistance. 
Simocyclinone D8, an aminocoumarin antibiotic with a completely new mode of action30, 36, 
showed similar activity against E. coli DNA gyrase as novobiocin, but less activity against 
S. aureus DNA gyrase. Its effect on S. aureus topoisomerase IV was weak and it was 
essentially inactive against the corresponding E. coli enzyme (Table III.3)87.  
Novclobiocin 101, which is very similar in structure to clorobiocin but lacks the chlorine in 
position 8 of the aminocoumarin moiety (Figure III.20) showed 8-fold lower inhibitory 
activity against S. aureus DNA gyrase than clorobiocin (Table III.3). If the chlorine atom of 
clorobiocin is replaced by a methyl group (novclobiocin 102), there is 2-fold reduction in 
activity. These biochemically determined ratios of activities between clorobiocin, 
novclobiocin 101, and novclobiocin 102 are identical to those determined earlier in a disk 
diffusion assay against Bacillus subtilis32.  
When the acyl substituent at position 3 of the deoxysugar of novobiocin is removed, 
resulting in novclobiocin 103, activity against S. aureus DNA gyrase is reduced by a factor 
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of 100. When the methyl group of the 4-methoxy group at the deoxysugar moiety of 
clorobiocin is additionally removed, activity is completely lost (novclobiocin 105).  
Novclobiocins 217 and 225 are clorobiocin derivatives in which the alkyl side chains of the 
4-hydroxy-benzoyl moieties have been modified (Figure III.20)4. They have been identified 
as very potent inhibitors of the growth of S. aureus ATCC 29213 and the methicillin-
resistant S. aureus strain ATCC 43300 with MIC values of <0.06, equal to the parent 
compound clorobiocin5. Our study shows that these compounds are highly potent 
inhibitors of S. aureus DNA gyrase in vitro, with inhibitory concentrations of 1 nM. In 
contrast, the changes in the acyl side chains that provided increased DNA gyrase 
inhibitory activity, led to a lower inhibition of topoisomerase IV. It is also remarkable that 
the E. coli topoisomerase IV is more sensitive to the aminocoumarin antibiotics tested than 
the S. aureus enzyme. The results indicate that the presence of the 3``-MePC moiety and 
the natural occurring 3-dimethylallyl-4-hydroxy-benzoic acid side chain are of importance 
for topoisomerase IV inhibition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table III.3:  
Inhibitory activity of aminocoumarin antibiotics against DNA gyrase and topoisomerase IV from Escherichia 
coli and Staphylococcus aureus. The concentration [µM] of antibiotic that caused 50% inhibition (IC50) of 
DNA gyrase supercoiling and topoisomerase IV decatenation is given. DNA gyrase and topoisomerase IV 
activities were determined in the presence of 700 and 100 mM potassium glutamate, respectively. Each 
assay was repeated at least twice and the IC50 values were determined based on intensity of either the 
supercoiled DNA or decatenated DNA gel bands. 
IC50 (µM) 
E. coli S. aureus 
 
compound  
name 
DNA gyrase topo IV DNA gyrase topo IV 
novobiocin 0.08 10 0.01 20 
clorobiocin 0.03 3 0.006 10 
coumermycin A1 0.03 5 0.006 100 
simocyclinone D8 0.1 >10 2 17 
novclobiocin 101 0.3 3 0.05 35 
novclobiocin 102 0.03 0.3 0.01 5 
novclobiocin 103 0.1 >10 1 >50 
novclobiocin 105 >100 >100 >100 >100 
novclobiocin 217 0.006 8 0.001 >50 
novclobiocin 225 0.006 8 0.001 >50 
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III.4. Inactivation of cloHIJK (encoding for Ring B) in the biosynthetic 
gene cluster of clorobiocin and heterologous expression of the 
modified cluster 
 
Ring B of aminocoumarins has been linked to their toxicity. In order to replace the genuine 
Ring B of clorobiocin with less toxic analogous by mutasynthesis experiments, the 
biosynthesis of the genuine Ring B would need to be abolished.  
Using RED/ET-mediated recombination, we replaced the coding sequence of cloHIJK with 
an apramycin resistance gene, resulting in cosmid clo-SA3 (Figure III.22). The resistance 
cassette was subsequently removed by restriction digestion and religation, using XbaI and 
SpeI sites introduced into the PCR primer sequence as described previously. This cloHIJK 
deficient gene cluster was integrated into the genome of S. coelicolor M512, resulting in S. 
coelicolor M512 (clo-SA4) (Figure III.22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.22: 
Gene deletion using the apramycin resistance cassette (aac(3)IV) from pIJ773 containing flanking XbaI and 
SpeI restriction sites. 
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gene cluster produced this antibiotic. However, feeding of Ring B (2 mg per 80 ml culture 
medium) restored production of clorobiocin, as confirmed by HPLC analysis and UV 
spectra comparison to an authentic reference compound (data not shown). Therefore, the 
inactivation of cloHIJK had led to the abolishment of the production of ring B, but had not 
affected the subsequent steps of clorobiocin biosynthesis. 
The only purchasable Ring B analogous 6-Amino-4-methyl-quinolin-2-ol (Matrix Scientific; 
Figure III.23) was fed under the same conditions as Ring B to S. coelicolor M512(clo-
SA4). Until now, no product formation with this Ring B analogous could be observed by 
HPLC analysis. 
 
 
 
 
 
 
 
Figure III.23: 
Ring B analogue 6-amino-4-methyl-quinolin-2-ol.
N
NH2
CH3
HO
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IV. DISCUSSION 
IV.1. Generation and activity test of novclobiocin 401, a clorobiocin 
derivative containing the catechol moiety 3,4-dihydroxybenzoic 
acid 
 
The present study provides an example for the rational design and production of a 
structurally modified antibiotic by a synthetic biology approach. The main aim was to 
exchange the structure of Ring A in clorobiocin by a catechol moiety, and in that way 
imitate a siderophore and facilitate the transport of the antibiotic inside the cell. The 
chemical synthesis of a clorobiocin derivative with a modified Ring A moiety is not 
straightforward, since a clorobiocin derivative lacking Ring A (e.g. containing only Rings B 
and C) can not be obtained from any producer strain, due to the fact that Ring A is the 
starter moiety for clorobiocin biosynthesis. Alternatively, the de novo chemical synthesis of 
an entire aminocoumarin antibiotic is a complicated multi-step procedure63. 
 
Our engineering strategy involved genes from four different organisms: i) the Gram-
negative organism E. coli as the source of ubiC, which encodes an enzyme of an anabolic 
pathway; ii) the Gram-positive organism Corynebactericum cyclohexanicum as the source 
of pobA, encoding an enzyme of a catabolic pathway; iii) Streptomyces 
roseochromogenes as the source of the biosynthetic gene cluster of clorobiocin, which 
was modified by deletion of cloQ; and iv) Streptomyces coelicolor M512 as host for 
heterologous expression. S. coelicolor M51238 is a derivate of the strain S. coelicolor A3(2). 
Strain M512 does not produce three of the genuine antibiotics of strain A3(2), i.e. 
methylenomycin, actinorhodin and undecylprodigiosine, which facilitates the detection and 
isolation of heterologously produced compounds. The modified clorobiocin gene cluster 
was stably integrated into the chromosome of this organism, and the synthetic operon 
containing ubiC and pobA under control of the strong constitutive ermE* promoter was 
expressed from a replicative plasmid. This strategy resulted in the efficient production of 
the desired compound novclobiocin 401, a clorobiocin derivative in which the genuine Ring 
A is replaced with a 3,4-DHBA moiety.  
The yield of novclobiocin 401 exceeded that of clorobiocin reported for both the wild type 
and for a heterologous producer strain31. Even without extensive optimization experiments, 
novclobiocin 401 represented a major compound in the culture extract, what facilitated the 
preparative isolation of this compound. The production of novclobiocin 401 did not result in 
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any impairment of growth of the heterologous producer strain. Apparently, both the 
diversion of chorismate for the production of 3,4-DHBA and the accumulation of the potent 
gyrase inhibitor novclobiocin 401 were tolerated well. Self-resistance of the heterologous 
producer strain was expected, since the clorobiocin gene cluster, contained in clo-SA2, 
carries an aminocoumarin resistance gene31.  
In vitro investigation of the inhibitory effect of this compound on the DNA gyrase of E. coli 
and S. aureus showed no change of activity in comparison to the parent compound 
clorobiocin. This confirms that the structure of Ring A is of little importance for the 
interaction of aminocoumarin antibiotics with their principal target, and can be modified to 
introduce desirable motifs into the molecule. It should be noted that the IC50 of 
novclobiocin 401 against the gyrase of E. coli and Staphylococcus aureus is two to three 
orders of magnitude lower than that of modern fluoroquinolones113, confirming the strong 
potency of aminocoumarins.  
Novclobiocin 401, containing a catechol motif, showed higher antibacterial activity than its 
parent compound clorobiocin against E. coli mutants defective in the TolC-dependent 
efflux pump. When tonB was additionally deleted, the activity of novclobiocin 401 was 
reduced eightfold (as calculated from the MIC values), while the activity of clorobiocin 
remained unchanged. TonB supplies the energy for the catechol siderophore transporters 
Cir, Fiu and FepA, and therefore this result strongly suggests that these transporters are 
involved in the active import of novclobiocin 401.  
Previous experiments showed that especially Cir and Fiu have a broad substrate 
specificity and can import catechol compounds of different structures50. Uptake of drug-
siderophore conjugates by Cir and Fiu has been demonstrated previously, like for 
cephalosporin-catechol conjugates50, 79. However, in these examples the catechol moiety 
conjugated to the antibiotic added considerably to the molecular weight of the drug, and 
even the size of the catechol moiety often exceeded the size of the antibiotic moiety. In the 
present study, a pre-existing moiety (i.e. Ring A) of the antibiotic was replaced by a 
catechol moiety, and the molecular weight of the new catechol compound (645 Da) was 
lower than that of the parent compound clorobiocin (697 Da).  
Though novclobiocin 401 was transported into E. coli cells under involvement of TonB-
dependent transporters, it did not show higher activity than clorobiocin against wild-type 
and ΔentC mutants (with production of the natural siderophore enterobactin abolished) of 
E. coli. The MIC values of clorobiocin and novclobiocin 401 against E. coli ΔentC mutants 
were 23 and 95 μg/ml, respectively. Under identical conditions, the MICs against 
ΔentC/ΔtolC double mutants were 12 and 6 μg/ml, respectively. These results suggest that 
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novclobiocin 401 is more rapidly exported than clorobiocin by TolC-dependent drug efflux 
pumps. The introduction of a catechol moiety into the clorobiocin molecule therefore had 
the desired effect to facilitate active import by catechol siderophore transporters, but also 
the undesired effect to accelerate TolC-dependent efflux. Future attempts to improve the 
activity of aminocoumarins against Gram-negative organism may therefore aim at a 
reduced efflux, either by modification of the drug or by combination with an efflux pump 
inhibitor, and at a further improvement of active import, e.g. by inclusion of a 2,3-DHBA 
moiety, which is the catechol moiety present in enterobactin.  
 
The generation of a clorobiocin derivative with a 2,3-DHBA moiety by combinatorial 
biosynthesis proved more complicated because of the requirement of its activation by 
adenylation prior to the acceptance by the aminocoumarin acyl ligase. We identified a 
suitable 2,3-DHBA AMP ligase from B. subtilis75, but it failed to be functional in S. 
coelicolor M512. Further attempts to produce 2,3-DHBA in the same host by introducing a 
plasmid containing the necessary genes from the griseobactin gene cluster of 
Streptomcyes griseus89 were also unsuccessful, probably because of inefficient expression 
of the genes from this construct. 
We only obtained the desired 2,3-DHBA clorobiocin derivate when we fed 2,3-DHBA to the 
heterologous host S. coelicolor M1154 (improved heterologous expression strain derived 
from S. coelicolor45) containing clo-SA2 and the griseobactin-derived construct. We think 
that 2,3-DHBA, fed to the culture medium, was activated by an AMP-ligase endogenous in 
M1154, probably encoded by the first gene in the hypothetical coelibactin gene cluster11, 
Sco7681. Although we have now obtained the desired compound, it is still to be tested in 
vitro and in vivo to see whether it is comparable imported as the 3,4-DHBA analogue 
novclobiocin 401. 
 
The major focus of this work was an improved influx of aminocoumarins into Gram-
negative bacteria. We have demonstrated that, at least in E. coli, it is the multidrug efflux-
pump, dependent on the membrane channel TolC, which is responsible for the high level 
of resistance. The previously reported high sensitivity of novobiocin to E. coli mutants, 
affected in cardiolipin metabolism116, 127, could well be due to an impaired function of the 
efflux pump in membranes diminished of that phospholipid. The increased activity shown 
by novclobiocin 401 against a TolC deficient E. coli strain is promising, and it must be 
noted that novclobiocin 401 (nor the 2,3-DHBA analogue) has not been tested in vivo 
against other bacteria yet. 
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All together, we are confident that the work presented in this thesis comprises an important 
advance in combinatorial biosynthesis of antibiotics and of aminocoumarins in particular 
towards an improvement of their bioactivity.  
 
 
IV.2. Inhibition of DNA gyrase and topoisomerase IV of 
Staphylococcus aureus and Escherichia coli by aminocoumarin 
antibiotics 
 
One part of the present work aimed at elucidating the contribution of different 
aminocoumarin structural elements to their inhibitory activity against DNA gyrase and 
topoisomerase IV of Gram-positive and Gram-negative bacteria, what would provide us 
with more knowledge for further rational improvement of this class of antibiotics.  
We established an optimized protocol for supercoiling and decatenation assays, and we 
determined the inhibitory activity of four naturally occurring aminocoumarin antibiotics and 
of several novclobiocins, compounds derived from clorobiocin and novobiocin, against 
DNA gyrase and topoisomerase IV from S. aureus and E. coli. 
In the supercoiling assay, S. aureus DNA gyrase requires the presence of high 
concentrations of K-Glu, whereas E. coli DNA gyrase had so far been assayed in the 
absence of this salt. For the first time, our study shows that the sensitivity of E. coli DNA 
gyrase towards the inhibition by aminocoumarins is considerably increased by K-Glu. 
Therefore, the concentration of K-Glu used in the assays needs to be considered when 
comparing the effect of inhibitors on E. coli and S. aureus DNA gyrase. The precise role of 
K-Glu in the catalytic mechanism of topoisomerases is unclear. Hiasa and co-workers52, 
provided evidence that K-Glu is not required for the binding of DNA to the catalytic domain 
of DNA gyrase, but rather for its binding to the C-terminal domain of GyrA and the resulting 
wrapping of DNA which enables DNA gyrase to catalyse the supercoiling reaction.  
Another theory is that DNA gyrase requires potassium for activity, and it has been shown 
that it stabilizes the GyrB subunit108. DNA Gyrase belongs to the GHKL family of enzymes 
(represented by gyrase, Hsp90, certain protein kinases, and the DNA mismatch protein 
MutL), and crystallographic and biochemical studies have revealed a distinct binding site 
for monovalent cations like K+ on these enzymes, which is important for catalytic activity56. 
This may explain the difference of the effects of K+ and Na+ on the type II topoisomerases. 
Assays with Na-Glu instead K-Glu showed no stimulatory effect for S. aureus DNA gyrase, 
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and we even found an inhibitory effect over E. coli DNA gyrase. Since this enzyme does 
nor require K-Glu, the most feasible explanation is that the sodium added with Na-Glu out-
competes the potassium present in the reaction buffer as 24 mM KCl; this would explain 
the weak activity observed when adding only 100 mM Na-Glu, concentration at which a 
proportion of DNA gyrase could still be reached by potassium; and it would also explain 
the lack of activity of E. coli enzyme with increasing concentration of NaCl. The results 
obtained with competition assays between Na-Glu and KCl or K-Glu did not support this 
hypothesis and more experiments are required to give further insights into DNA gyrase 
requirements of potassium and glutamate. 
Assays of inhibitory activity of aminocoumarin antibiotics reinforced the previous 
knowledge and provided further insights about the relevance of the different substituents 
on antibiotic activity. Out of the four naturally occurring aminocoumarin antibiotics, 
clorobiocin and coumermycin A1 had the highest inhibitory activity against all the enzymes 
tested, and clorobiocin had the lowest IC50 toward topoisomerase IV of both E. coli and S. 
aureus. Manipulation of substituents35 at position 3``-OH of noviose confirmed that the 
presence of MePC is essential for high inhibition of both DNA gyrase and topoisomerase 
IV. Furthermore, elimination of the methyl group at position 8`` of noviose rendered the 
compound (novclobiocin 105) completely inactive against all the enzymes tested, which 
indicate that hydrophobic contacts between this methyl group and a hydrophobic path of 
the enzymes play a prominent role44, 64. One of the most exciting results is the obtaining of 
clorobiocin and novobiocin derivates with stronger antibiotic activity than the natural 
compounds. In this way, modification of the Ring A, attached to the amino group of the 
coumarin ring, provided higher activity against DNA gyrase, particularly against E. coli 
enzyme, although with lost of activity against topoisomerase IV from both microorganisms. 
Therefore, our experiments suggest that the most active compounds against S. aureus 
and E. coli type II topoisomerases contain an 8``-CH3 group, a MePC moiety at position 3`` 
and an 8`-CH3 group. 
These biochemical data suggest that in vitro DNA gyrase is the primary target of all 
investigated aminocoumarin antibiotics. Fujimoto-Nakamura and co-workers42 have shown 
that cultivation of S. aureus in the presence of novobiocin results not only in the selection 
of mutants with altered DNA gyrase, but also in mutations of topoisomerase IV as a 
second step in resistance development. Therefore, topoisomerase IV may not be 
completely irrelevant as target of aminocoumarins in S. aureus, at least at higher antibiotic 
concentrations. 
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Another group of topoisomerases inhibitors are the synthetically generated 
fluoroquinolones, which interact with the GyrA and ParC subunits of DNA gyrase and 
topoisomerase IV respectively. Resistance against the fluoroquinolones is rapidly 
emerging, usually by mutations near the active site tyrosines of GyrA or ParC29. Agents 
that target type II topoisomerases in a different way than fluoroquinolones would offer a 
possibility to overcome this resistance while still exploiting the same validated target. The 
combination of fluoroquinolones with aminocoumarins, which are highly potent inhibitors of 
the GyrB and ParE subunits, may offer a strategy to provide effective antibacterial therapy 
with reduced risk of resistance development. In vitro studies have shown that S. aureus 
mutants that are simultaneously resistant to both fluoroquinolones and aminocoumarins 
arise only at very low frequency and might therefore not be selected if those agents were 
used as combination therapy117. These considerations may warrant the development and 
evaluation of new aminocoumarin antibiotics. The assay methods developed here can be 
useful in such approach. 
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